1374415	fibrinogen	be with	beta 3 localization to focal contact	Specifically , FG cells expressing beta 3 acquire the capacity to attach and spread on vitronectin as well as fibrinogen with beta 3 localization to focal contacts .	2244	fibrinogen	Gene	1934	beta 3	Gene
1376732	RHAMM	acronym for	receptor for hyaluronan-mediated motility	It is named RHAMM , an acronym for receptor for hyaluronan-mediated motility .	3161	rhamm	Gene	3161	receptor for hyaluronan-mediated motility	Gene
1374413	l-selectin	bind to	structural feature of potential mammalian carbohydrate ligand s	Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .	6402	l-selectin	Gene	MESH:D002241	carbohydrate	Chemical
1374413	l-selectin	bind to	feature of potential mammalian carbohydrate ligand s	Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .	6402	l-selectin	Gene	MESH:D002241	carbohydrate	Chemical
1374413	l-selectin	bind to	carbohydrate	Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .	6402	l-selectin	Gene	MESH:D002241	carbohydrate	Chemical
1374413	l-selectin	bind to	structural feature of potential carbohydrate ligand s	Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .	6402	l-selectin	Gene	MESH:D002241	carbohydrate	Chemical
1374413	l-selectin	bind to	feature of potential carbohydrate ligand s	Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .	6402	l-selectin	Gene	MESH:D002241	carbohydrate	Chemical
1374413	carbohydrate	feature of	potential mammalian carbohydrate ligand s	Although L-selectin has been demonstrated to bind to carbohydrates , structural features of potential mammalian carbohydrate ligand -LRB- s -RRB- have not been well defined .	MESH:D002241	carbohydrate	Chemical	MESH:D002241	carbohydrate	Chemical
1572895	four rna virus	be in	Fischer rat thyroid	We compared the surface envelope glycoprotein distribution and the budding polarity of four RNA viruses in Fischer rat thyroid -LRB- FRT -RRB- cells and in CaCo-2 cells derived from a human colon carcinoma .	12081	virus	Species	10116	rat	Species
25568625	eswl treatment	be perform on	machine Siemens Model Lithostar Multiline	ESWL treatment is performed on the machine Siemens Model Lithostar Multiline , which has a combined ultrasonographic and fluoroscopic display , large energy density in order to obtain optimum focus -LRB- without damaging surrounding tissue -RRB- and minimal pain that on rare occasions requires for mild sedation-sedation .	9606	men	Species	9606	men	Species
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	disease with pattern of regression follow by relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease with pattern of regression follow by relapse raise from residual myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	incurable disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still incurable disease follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern of regression follow by multiple relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	myeloma	be	still disease with pattern of regression follow by relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease with pattern follow by relapse raise from myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	incurable disease with pattern follow by multiple relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern of regression follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by relapse raise from myeloma cell survive even in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still disease follow by multiple relapse raise from residual myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease follow by relapse raise from myeloma cell	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	still incurable disease with pattern follow by multiple relapse raise from residual myeloma cell survive	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	multiple myeloma	be	disease with pattern follow by multiple relapse raise from residual myeloma cell survive in patient	Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment .	MESH:D009101	myeloma	Disease	MESH:D009101	myeloma	Disease
25568637	patient	be with	multiple myeloma	In recent years there is a huge improvement in treatment of patients with multiple myeloma .	9606	patient	Species	MESH:D009101	myeloma	Disease
25568637	elderly patient	be with	multiple myeloma	So , the major challenge for hematologist is to translate this improvement in the elderly patients with multiple myeloma .	9606	patient	Species	MESH:D009101	myeloma	Disease
25568637	elderly patient	be with	multiple myeloma	Today , physicians are able to offer wider variety of treatment options for elderly patients with multiple myeloma .	9606	patient	Species	MESH:D009101	myeloma	Disease
25568637	elderly patient	be with	multiple myeloma	In the mode of sequencing treatment for elderly patients with multiple myeloma , our goal is to achieve and maintain maximal response while limiting treatment - related toxicities as much as possible .	9606	patient	Species	MESH:D009101	myeloma	Disease
1607381	gamma-adaptin binding	be block by	BFA	This was confirmed using an in vitro assay in which gamma-adaptin binding to TGN membranes was blocked by BFA and enhanced by GTP gamma S , similar to the binding of beta-COP to Golgi membranes .	MESH:C020361	gamma-adaptin	Chemical	MESH:D020126	bfa	Chemical
1607381	gamma-adaptin binding	enhance by	gtp gamma s	This was confirmed using an in vitro assay in which gamma-adaptin binding to TGN membranes was blocked by BFA and enhanced by GTP gamma S , similar to the binding of beta-COP to Golgi membranes .	MESH:C020361	gamma-adaptin	Chemical	MESH:D016244	gtp gamma s	Chemical
25497602	patient	be treat in	5 fraction deliver with CyberKnife Radiosurgical System	All patients were treated to 35-36.25 Gy in 5 fractions delivered with the CyberKnife Radiosurgical System -LRB- Accuray -RRB- .	9606	patient	Species	MESH:D000544	ad	Disease
25497602	patient	be	treat to 35-36.25 gy in 5 fraction deliver with CyberKnife Radiosurgical System	All patients were treated to 35-36.25 Gy in 5 fractions delivered with the CyberKnife Radiosurgical System -LRB- Accuray -RRB- .	9606	patient	Species	MESH:D000544	ad	Disease
25497602	Telangiectasias	use	vrs	Telangiectasias were graded using the Vienna Rectoscopy Score -LRB- VRS -RRB- .	MESH:D013684	telangiectasia	Disease	MESH:C564884	vrs	Disease
25497602	Telangiectasias	be	grade	Telangiectasias were graded using the Vienna Rectoscopy Score -LRB- VRS -RRB- .	MESH:D013684	telangiectasia	Disease	MESH:D000544	ad	Disease
25497602	2 rectal telangiectasia	be in	11 % of patient	Endoscopy revealed VRS Grade 2 rectal telangiectasias in 11 % of patients .	MESH:D013684	telangiectasia	Disease	9606	patient	Species
1374414	proto-oncogene product pp60c-src	of association be	pc12 synaptic vesicle	Specific association of the proto-oncogene product pp60c-src with an intracellular organelle , the PC12 synaptic vesicle .	6714	c-src	Gene	CVCL:0481	pc12	CellLine
1374414	c-src protein	be associate	pp60c-src pattern overlap	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be associate	pp60c-src immunofluorescent pattern overlap	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be specifically associate	pp60c-src pattern overlap	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be associate	pp60c-src pattern overlap with vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be specifically associate	pp60c-src immunofluorescent pattern overlap with vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	pp60c-src pattern	overlap with	synaptophysin	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	MESH:D016708	synaptophysin	Chemical
1374414	c-src protein	be associate	pp60c-src immunofluorescent pattern overlap with vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be associate	pp60c-src pattern overlap with synaptic vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be specifically associate	pp60c-src pattern overlap with synaptic vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be associate	pp60c-src immunofluorescent pattern overlap with synaptic vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	pp60c-src immunofluorescent pattern	overlap with	synaptophysin	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	MESH:D016708	synaptophysin	Chemical
1374414	c-src protein	be specifically associate	pp60c-src immunofluorescent pattern overlap with synaptic vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be specifically associate	pp60c-src immunofluorescent pattern overlap	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1374414	c-src protein	be specifically associate	pp60c-src pattern overlap with vesicle marker	The c-src protein was found to be specifically associated with synaptic vesicles since : -LRB- a -RRB- the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker , synaptophysin ; -LRB- b -RRB- a significant proportion -LRB- 44 % -RRB- of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction ; -LRB- c -RRB- an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction , and -LRB- d -RRB- pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles .	6714	c-src	Gene	6714	c-src	Gene
1315787	double infection	be with	Semliki Forest virus	Double infection of multinucleated L6 muscle cells with Semliki Forest virus and VSV at high multiplicities showed that the glycoprotein of each virus occupied intracellular domains which were devoid of the other respective glycoprotein .	MESH:D007239	infection	Disease	12081	virus	Species
1315314	sr alpha	be	wherein repopulate with sr alpha by translation of mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	repopulate with sr alpha by translation of mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	repopulate with sr alpha by translation	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	repopulate with sr alpha by translation of wild-type mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	wherein repopulate with sr alpha by in translation	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be repopulate with	sr alpha	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	wherein repopulate with sr alpha by in translation of wild-type mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	wherein repopulate with sr alpha by in translation of mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	wherein repopulate with sr alpha by translation	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	repopulate with sr alpha by in translation of wild-type mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	wherein repopulate with sr alpha	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	wherein repopulate with sr alpha by translation of wild-type mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	repopulate with sr alpha by in translation	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	sr alpha	be	repopulate with sr alpha by in translation of mrna transcript	The SR alpha mutants were analyzed using an in vitro system wherein SR alpha - deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts .	4481	sr alpha	Gene	4481	sr alpha	Gene
1315314	srp receptor	form	NH	These SRP receptors were likewise unable to form Gpp -LRB- NH -RRB- p stabilized complexes with the SRP .	6729	srp	Gene	MESH:D000641	nh	Chemical
1315314	gtp binding site	be in	alpha subunit of srp receptor	This mutant has provided information on the reaction step in protein translocation that involves the GTP binding site in the alpha subunit of the SRP receptor .	MESH:D006160	gtp	Chemical	6729	srp	Gene
1560033	calcium deposition	occur regardless of	addition of beta glycerophosphate	Calcium deposition in the extracellular matrix occurred regardless of the addition of beta glycerophosphate to the culture medium .	MESH:D002118	calcium	Chemical	MESH:C031463	beta glycerophosphate	Chemical
1560033	calcium deposition	occur regardless of	addition of beta glycerophosphate to culture medium	Calcium deposition in the extracellular matrix occurred regardless of the addition of beta glycerophosphate to the culture medium .	MESH:D002118	calcium	Chemical	MESH:C031463	beta glycerophosphate	Chemical
1560033	retinoic acid	be	when add to hypertrophic chondrocyte culture	When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .	MESH:D014212	retinoic acid	Chemical	MESH:D006984	hypertrophic	Disease
1560033	retinoic acid	be	add to hypertrophic chondrocyte culture between day 1	When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .	MESH:D014212	retinoic acid	Chemical	MESH:D006984	hypertrophic	Disease
1560033	retinoic acid	be	when add to hypertrophic chondrocyte culture between day 1	When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .	MESH:D014212	retinoic acid	Chemical	MESH:D006984	hypertrophic	Disease
1560033	retinoic acid	be add to	hypertrophic chondrocyte culture	When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated .	MESH:D014212	retinoic acid	Chemical	MESH:D006984	hypertrophic	Disease
25511509	background Sheep	be	valuable resource	Background Sheep are valuable resources for the animal fibre industry .	9940	sheep	Species	MESH:D002244	c	Chemical
25511509	background Sheep	be resource for	animal fibre industry	Background Sheep are valuable resources for the animal fibre industry .	9940	sheep	Species	MESH:D009584	n	Chemical
25511509	background Sheep	be valuable resource for	animal fibre industry	Background Sheep are valuable resources for the animal fibre industry .	9940	sheep	Species	MESH:D009584	n	Chemical
25511509	background Sheep	be	resource	Background Sheep are valuable resources for the animal fibre industry .	9940	sheep	Species	MESH:D002244	c	Chemical
25511509	microarray result	be verify by means of	pcr	The microarray results were verified by means of quantitative PCR .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25511509	microarray result	be verify by means of	quantitative pcr	The microarray results were verified by means of quantitative PCR .	MESH:D002244	c	Chemical	MESH:D009584	n	Chemical
25511509	cluster analysis	could distinguish	body side skin	Cluster analysis could distinguish the body side skin and the groin skin .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	cluster analysis	could distinguish	groin skin	Cluster analysis could distinguish the body side skin and the groin skin .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	four category	regulation of	receptor binding	Based on the Database for Annotation , Visualization and Integrated Discovery -LRB- DAVID -RRB- , 38 of the differentially expressed genes were classified into four categories , namely regulation of receptor binding , multicellular organismal process , protein binding and macromolecular complex .	MESH:D002244	c	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	show	significant difference in they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	difference in	they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	difference in	they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	show	significant difference	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	show	difference in they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	show	significant difference in they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	show	significant difference	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	significant difference in	they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	show	difference	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	show	significant difference in they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	show	difference in they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	significant difference in	they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	significant difference in	they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	difference in	they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	significant difference in	they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	show	difference	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	show	difference in they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	significant difference	be in	they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	show	significant difference in they expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	187 protein spot	show	difference in they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein spot	difference in	they respective expression level	Proteomic study revealed that 187 protein spots showed significant -LRB- p < 0.05 -RRB- differences in their respective expression levels .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	46 protein entry	be	further identify	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	46 protein entry	be	among they further identify by maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein entry	be	further identify	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	46 protein entry	be	among they identify by maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	46 protein entry	be	identify	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein entry	be identify by	maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	46 protein entry	be identify by	maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein entry	be further identify by	maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein entry	be	among they identify by maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	46 protein entry	be further identify by	maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein entry	be	among they further identify by maldi-tof/ms analysis	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	protein entry	be	identify	Among them , 46 protein entries were further identified by MALDI-TOF/MS analyses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	many	be	possibly associate	Conclusions Microarray analysis revealed thousands of differentially expressed genes , many of which were possibly associated with wool growth .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	many	be	associate	Conclusions Microarray analysis revealed thousands of differentially expressed genes , many of which were possibly associated with wool growth .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	potential gene family	might participate in	hair growth regulation	Several potential gene families might participate in hair growth regulation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	several potential gene family	might participate in	hair growth regulation	Several potential gene families might participate in hair growth regulation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	supplementary material	online version of	article	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	supplementary material	version of	article	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	electronic material	version of	article	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	supplementary material	contain	supplementary material	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	electronic material	online version of	article	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	electronic supplementary material	online version of	article	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	electronic supplementary material	contain	supplementary material	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25511509	electronic supplementary material	version of	article	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D002244	c	Chemical
25511509	electronic material	contain	supplementary material	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12863-014-0144-1 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1374417	rate limit enzyme	be in	cholesterol biosynthetic pathway	We have raised two monospecific antibodies against synthetic peptides derived from the membrane domain of the ER glycoprotein 3-hydroxy-3 - methylglutaryl coenzyme A -LRB- HMG-CoA -RRB- reductase , the rate limiting enzyme in the cholesterol biosynthetic pathway .	10116	rat	Species	MESH:D002784	cholesterol	Chemical
1374067	pkc epsilon-related kinase associate	be with	cytokeratin	PKC epsilon-related kinase associates with and phosphorylates cytokeratin 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	human specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with human specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	human epithelial cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with human cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	epithelial cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	epithelial specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	human epithelial specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with human epithelial specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	associate with	human cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with epithelial cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with human epithelial cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	pkc epsilon	be find	associate with epithelial specific cytokeratin	A 40-kD protein kinase C -LRB- PKC -RRB- epsilon related activity was found to associate with human epithelial specific cytokeratin -LRB- CK -RRB- polypeptides 8 and 18 .	5581	pkc epsilon	Gene	10116	rat	Species
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in cell	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in intact cell in kinase assay	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in kinase assay	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in kinase assay	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in cell in kinase assay	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation in intact cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation in cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in intact cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in intact cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in intact cell in kinase assay	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in cell in kinase assay	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in intact cell	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18 in intact cell	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation in cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation of ck8/18 in cell	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate	inhibit	phosphorylation in intact cell in kinase assay with ck8/18 immunoprecipitate	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1374067	peptide pseudosubstrate specific	inhibit	phosphorylation of ck8/18	A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates .	10116	rat	Species	3856	ck8	Gene
1577863	hsp47	be show	coprecipitate by treatment of cell with anti-hsp47	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment of intact cell with anti-hsp47 with anticollagen antibody	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment of intact cell with anti-hsp47	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment of intact cell with anti-hsp47 with antibody	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment with anti-hsp47 with anticollagen antibody	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment with anti-hsp47	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment of cell with anti-hsp47 with anticollagen antibody	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment of cell with anti-hsp47 with antibody	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1577863	hsp47	be show	coprecipitate by treatment with anti-hsp47 with antibody	HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies .	871	hsp47	Gene	871	hsp47	Gene
1572893	regulation	modulate	activity of myristoylcoa	Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .	MESH:D009584	n	Chemical	MESH:C040349	myristoylcoa	Chemical
1572893	regulation	be in	saccharomyces cerevisiae	Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .	MESH:D009584	n	Chemical	4932	saccharomyces cerevisiae	Species
1572893	protein n	enzyme with	order bi bi reaction	Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .	MESH:D009584	n	Chemical	MESH:D001729	bi bi	Chemical
1572893	essential enzyme	be with	order bi bi reaction	Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA : protein N - myristoyltransferase -LRB- NMT -RRB- , an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins .	MESH:D009584	n	Chemical	MESH:D001729	bi bi	Chemical
1572893	faa1 gene	have	have isolate by complementation	The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1 gene	have	have isolate by genetic complementation of faal mutant	The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1 gene	have	have isolate by genetic complementation of mutant	The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1 gene	have	have isolate by genetic complementation	The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1 gene	have	have isolate by complementation of faal mutant	The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1 gene	have	have isolate by complementation of mutant	The FAA1 -LRB- fatty acid activation -RRB- gene has been isolated by genetic complementation of a faal mutant .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	copy gene	specify	chain acylcoa synthetase	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	single copy gene	specify	chain acylcoa synthetase	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	single copy gene	specify	long chain acylcoa synthetase	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	copy gene	specify	long chain acylcoa synthetase	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	copy gene	specify	chain acylcoa synthetase of 700 amino acid	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	single copy gene	specify	long chain acylcoa synthetase of 700 amino acid	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	copy gene	specify	long chain acylcoa synthetase of 700 amino acid	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	single copy gene	specify	chain acylcoa synthetase of 700 amino acid	This single copy gene , which maps to the right arm of chromosome XV , specifies a long chain acylCoA synthetase of 700 amino acids .	MESH:D009584	n	Chemical	MESH:D000214	acylcoa	Chemical
1572893	faa1	be	require for utilization for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of exogenous myristate for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate by NMT for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization by NMT for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be require for	synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of exogenous myristate by NMT for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate by NMT for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate by NMT for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of myristate by NMT for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization by NMT	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be require for	utilization	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of myristate for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization by NMT for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be require for	synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate by NMT for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of myristate for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization by NMT for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization by NMT for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of exogenous myristate by NMT for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of exogenous myristate for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of exogenous myristate by NMT for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of myristate for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of myristate for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of myristate by NMT for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of exogenous myristate by NMT for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of exogenous myristate for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization by NMT for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of myristate for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate by NMT	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate by NMT for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of exogenous myristate by NMT for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of exogenous myristate for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate by NMT for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	utilization of myristate	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization by NMT for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of exogenous myristate for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization by NMT for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate by NMT	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of myristate by NMT for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization of myristate by NMT for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate by NMT for synthesis	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization by NMT for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	require for utilization of myristate by NMT for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate by NMT for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	utilization of exogenous myristate	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization by NMT for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate for synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	utilization of myristate by NMT	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	at 36 degree c require for utilization of myristate for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be	require for utilization by NMT for synthesis of several phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be require for	utilization of exogenous myristate by NMT	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	utilization by NMT	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate by NMT for synthesis of phospholipid species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1572893	faa1	be require for	synthesis of species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009584	n	Chemical
1572893	faa1	be	at 36 degree c require for utilization of exogenous myristate by NMT for synthesis of several species	At 36 degrees C , FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species .	854495	faa1	Gene	MESH:D009226	myristate	Chemical
1315318	beta-nerve growth factor	have	testosterone-downregulated low-affinity receptor on cell	beta-Nerve growth factor -LRB- NGF -RRB- is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis .	310738	beta-nerve growth factor	Gene	MESH:D013739	testosterone	Chemical
1315318	beta-nerve growth factor	have	testosterone-downregulated low-affinity receptor on sertoli cell	beta-Nerve growth factor -LRB- NGF -RRB- is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis .	310738	beta-nerve growth factor	Gene	MESH:D013739	testosterone	Chemical
1315318	beta-nerve growth factor	have	testosterone-downregulated low-affinity receptor	beta-Nerve growth factor -LRB- NGF -RRB- is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis .	310738	beta-nerve growth factor	Gene	MESH:D013739	testosterone	Chemical
1315318	ngf	stimulate dna synthesis with	preleptotene spermatocyte at onset of meiosis	NGF was shown to stimulate in vitro DNA synthesis of seminiferous tubule segments with preleptotene spermatocytes at the onset of meiosis while other segments remained nonresponsive .	310738	ngf	Gene	MESH:C536875	meiosis	Disease
1577856	pmn	be label with	fluorescent probe nbd-phallicidin	PMN were labeled with fluorescent probe NBD-phallicidin to measure filamentous actin and Texas red to assess cell thickness .		pmn	Disease	MESH:C028877	nbd-phallicidin	Chemical
1577856	pmn	be label with	probe nbd-phallicidin	PMN were labeled with fluorescent probe NBD-phallicidin to measure filamentous actin and Texas red to assess cell thickness .		pmn	Disease	MESH:C028877	nbd-phallicidin	Chemical
1618903	different extracellular domain	be	involve	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different extracellular domain	be involve in	function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different domain	be	involve	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	extracellular domain	be involve in	different function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	domain	be involve in	function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different domain	be involve in	different function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	extracellular domain	be	involve	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different extracellular domain	be involve in	different function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	extracellular domain	be involve in	function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	domain	be involve in	different function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different domain	be involve in	function	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	domain	be	involve	Different extracellular domains of the neural cell adhesion molecule -LRB- N - CAM -RRB- are involved in different functions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	functional role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	functional role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	diverse role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	diverse role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	diverse role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	diverse functional role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	functional role	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	functional role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	diverse functional role	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	functional role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	functional role	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	diverse functional role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	diverse functional role	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	diverse functional role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	neural cell adhesion molecule	engage in	diverse role in cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	diverse functional role	be in	neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	cell adhesion molecule	engage in	diverse functional role in neural cell interaction	The neural cell adhesion molecule -LRB- N-CAM -RRB- engages in diverse functional roles in neural cell interactions .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	functional property	be in	cell interaction	To investigate the functional properties of the different structural domains of the molecule in cell interactions and signal transduction to the cell interior , we have synthesized , in a bacterial expression system , the individual domains and tandem sets of individual domains as protein fragments .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	protein fragment	promote	neurite outgrowth	These protein fragments were tested for their capacity to influence adhesion and spreading of neuronal cell bodies , promote neurite outgrowth , and influence cellular migration patterns from cerebellar microexplants in vitro .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	influence	be increase by	domain ii	Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	influence	be	increase	Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	influence	be	increase by ig-like domain i by domain ii	Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	influence	be increase by	domain i	Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	influence	be increase by	ig-like domain i	Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	influence	be	increase by domain i by domain ii	Outgrowth of astrocytic processes from the explant core was influenced only by Ig - like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II , III , IV , and V , and not influenced by the combined type III repeats I-II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	concentration	be increase by	ig-like domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	concentration	be	increase	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	intracellular concentration	be increase by	domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	intracellular concentration	be	increase	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	concentration	be increase by	domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	intracellular concentration	be increase by	only domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	intracellular concentration	be increase by	only ig-like domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	concentration	be increase by	only domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	intracellular concentration	be increase by	ig-like domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	concentration	be increase by	only ig-like domain	Intracellular concentrations of Ca2 + and pH values were increased only by the Ig-like domains I and II .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	domain	different	functional role in cell recognition	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	functional role	be in	cell recognition	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	functional role	domain of	n-cam subserve	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different domain	different	functional role in cell recognition	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different domain	different	functional role	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	domain	different	role in cell recognition	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	domain	different	functional role	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	functional role	different domain of	n-cam subserve	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618903	different domain	different	role in cell recognition	These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction , and are functionally competent without nervous system-derived carbohydrate structures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to heparin-binding synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived heparin-binding peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived heparin-binding synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived heparin-binding peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to heparin-binding synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D008545	melanoma	Disease
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to heparin-binding peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to heparin-binding peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to fibronectin-derived heparin-binding synthetic peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D006493	heparin	Chemical
1607392	cell surface heparan sulfate proteoglycan	initiate	mouse melanoma cell adhesion to peptide	Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived , heparin-binding synthetic peptide .	MESH:D013431	sulfate	Chemical	MESH:D008545	melanoma	Disease
1607392	synthetic peptide fn-c/h ii	peptide from	33-kd chain-derived fragment of fibronectin	Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .	MESH:D006859	h ii	Chemical	14268	fibronectin	Gene
1607392	cell surface heparan sulfate proteoglycan	initiate	cell adhesion to synthetic peptide fn-c/h ii	Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .	MESH:D013431	sulfate	Chemical	MESH:D006859	h ii	Chemical
1607392	metastatic mouse melanoma cell	from proteoglycan be	hspg	Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .	MESH:D008545	melanoma	Disease	15529	hspg	Gene
1607392	cell surface heparan sulfate proteoglycan	initiate	cell adhesion to peptide fn-c/h ii	Cell surface heparan sulfate proteoglycan -LRB- HSPG -RRB- from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II , a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin .	MESH:D013431	sulfate	Chemical	MESH:D006859	h ii	Chemical
1607392	mouse melanoma cell adhesion	be sensitive to	heparin	Mouse melanoma cell adhesion to FN-C/H II was sensitive to soluble heparin and pretreatment of mouse melanoma cells with heparitinase .	MESH:D008545	melanoma	Disease	MESH:D006493	heparin	Chemical
1607392	mouse melanoma cell adhesion	be sensitive to	soluble heparin	Mouse melanoma cell adhesion to FN-C/H II was sensitive to soluble heparin and pretreatment of mouse melanoma cells with heparitinase .	MESH:D008545	melanoma	Disease	MESH:D006493	heparin	Chemical
1607392	mouse melanoma cell hspg	be label with	sulfate	Mouse melanoma cell HSPG was metabolically labeled with -LSB- 35S -RSB- sulfate and extracted with detergent .	MESH:D008545	melanoma	Disease	MESH:D013431	sulfate	Chemical
1607392	mouse melanoma cell hspg	be metabolically label with	sulfate	Mouse melanoma cell HSPG was metabolically labeled with -LSB- 35S -RSB- sulfate and extracted with detergent .	MESH:D008545	melanoma	Disease	MESH:D013431	sulfate	Chemical
1607392	hspg	purify from	mouse melanoma cell	Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein .	15529	hspg	Gene	MESH:D008545	melanoma	Disease
1607392	hspg	purify from	mouse melanoma cell grow	Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein .	15529	hspg	Gene	MESH:D008545	melanoma	Disease
1607392	hspg	purify from	mouse melanoma cell grow in vivo	Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein .	15529	hspg	Gene	MESH:D008545	melanoma	Disease
1607392	hspg	be	integral plasma membrane component by virtue of its binding to Octyl Sepharose affinity column	This HSPG is an integral plasma membrane component by virtue of its binding to Octyl Sepharose affinity columns and that anti-HSPG antibody staining exhibited a cell surface localization .	15529	hspg	Gene	MESH:C059676	octyl	Chemical
1607392	hspg	be	plasma membrane component by virtue of its binding to Octyl Sepharose affinity column	This HSPG is an integral plasma membrane component by virtue of its binding to Octyl Sepharose affinity columns and that anti-HSPG antibody staining exhibited a cell surface localization .	15529	hspg	Gene	MESH:C059676	octyl	Chemical
1607392	hspg	be anchor through	phosphatidylinositol	The HSPG is anchored to the cell surface through phosphatidylinositol -LRB- PI -RRB- linkages , as evidenced in part by the ability of PI-specific phospholipase C to eliminate binding of the detergent-extracted HSPG to Octyl Sepharose .	15529	hspg	Gene	MESH:D010716	phosphatidylinositol	Chemical
1607392	hspg	be	anchor to cell surface through phosphatidylinositol	The HSPG is anchored to the cell surface through phosphatidylinositol -LRB- PI -RRB- linkages , as evidenced in part by the ability of PI-specific phospholipase C to eliminate binding of the detergent-extracted HSPG to Octyl Sepharose .	15529	hspg	Gene	MESH:D010716	phosphatidylinositol	Chemical
1607392	mouse melanoma hspg core protein	could	could metabolically label with 3h-ethanolamine	Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .	MESH:D008545	melanoma	Disease	MESH:D004983	3h-ethanolamine	Chemical
1607392	mouse melanoma hspg core protein	could	could label with 3h-ethanolamine	Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .	MESH:D008545	melanoma	Disease	MESH:D004983	3h-ethanolamine	Chemical
1607392	mouse melanoma hspg core protein	could	furthermore could metabolically label with 3h-ethanolamine	Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .	MESH:D008545	melanoma	Disease	MESH:D004983	3h-ethanolamine	Chemical
1607392	mouse melanoma hspg core protein	could	furthermore could label with 3h-ethanolamine	Furthermore , the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine .	MESH:D008545	melanoma	Disease	MESH:D004983	3h-ethanolamine	Chemical
1607392	heparitinase-treated 125i-labeled hspg	bind	fn-c/h ii	However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .	MESH:C492712	125i	Chemical	MESH:D006859	h ii	Chemical
1607392	125i-labeled hspg	bind	fn-c/h ii	However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .	MESH:C492712	125i	Chemical	MESH:D006859	h ii	Chemical
1607392	hspg	bind	fn-c/h ii	However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .	15529	hspg	Gene	MESH:D006859	h ii	Chemical
1607392	heparitinase-treated hspg	bind	fn-c/h ii	However , heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II , suggesting that HS , and not HSPG core protein , binds FN-C/H II .	15529	hspg	Gene	MESH:D006859	h ii	Chemical
1607392	phosphatidylinositol-anchored hspg	initiate	recognition to fn-c/h ii	These data support the hypothesis that a phosphatidylinositol-anchored HSPG on mouse melanoma cells -LRB- MPIHP-63 -RRB- initiates recognition to FN-C/H II , and implicate PI-associated signal transduction pathways in mediating melanoma cell adhesion to this defined ligand .	MESH:D010716	phosphatidylinositol	Chemical	MESH:D006859	h ii	Chemical
1607392	hspg	initiate	recognition to fn-c/h ii	These data support the hypothesis that a phosphatidylinositol-anchored HSPG on mouse melanoma cells -LRB- MPIHP-63 -RRB- initiates recognition to FN-C/H II , and implicate PI-associated signal transduction pathways in mediating melanoma cell adhesion to this defined ligand .	15529	hspg	Gene	MESH:D006859	h ii	Chemical
1315784	yeast cap protein	be	like chicken cap protein inhibit by pip2	Like chicken capping protein , yeast capping protein is inhibited by PIP2 .	4932	yeast	Species	9031	chicken	Species
1315784	yeast cap protein	be	like chicken protein inhibit by pip2	Like chicken capping protein , yeast capping protein is inhibited by PIP2 .	4932	yeast	Species	9031	chicken	Species
1315784	yeast cap protein	be inhibit like	chicken cap protein	Like chicken capping protein , yeast capping protein is inhibited by PIP2 .	4932	yeast	Species	9031	chicken	Species
1315784	yeast cap protein	be inhibit like	chicken protein	Like chicken capping protein , yeast capping protein is inhibited by PIP2 .	4932	yeast	Species	9031	chicken	Species
1315784	yeast cap protein	be inhibit by	pip2	Like chicken capping protein , yeast capping protein is inhibited by PIP2 .	4932	yeast	Species	854545	pip2	Gene
1315782	f3 molecule	be	member anchor by glycane-phosphatidylinositol	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	anchor by	glycane-phosphatidylinositol	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	MESH:D010716	glycane-phosphatidylinositol	Chemical
1315782	f3 molecule	be	member anchor to membrane	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	be	member anchor to membrane by glycane-phosphatidylinositol	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	be	member of immunoglobulin superfamily anchor	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	be	member of immunoglobulin superfamily anchor to membrane by glycane-phosphatidylinositol	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	be	member of immunoglobulin superfamily anchor to membrane	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	be	member anchor	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1315782	f3 molecule	be	member of immunoglobulin superfamily anchor by glycane-phosphatidylinositol	The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol , and is predominantly expressed on subsets of axons of the central and peripheral nervous system .	MESH:C056920	f3	Chemical	CVCL:0213	cho	CellLine
1318883	massive secretion	be in	cholera-induced diarrhea	The massive secretion of salt and water in cholera-induced diarrhea involves binding of cholera toxin -LRB- CT -RRB- to ganglioside GM1 in the apical membrane of intestinal epithelial cells , translocation of the enzymatically active A1-peptide across the membrane , and subsequent activation of adenylate cyclase located on the cytoplasmic surface of the basolateral membrane .	MESH:D012211	re	Chemical	MESH:D003967	diarrhea	Disease
1318883	isc response	be	at 20 degree c inhibit than response	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be strongly inhibit than	response	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be more strongly inhibit than	response to ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c more strongly inhibit than response to basolateral ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be inhibit at	20 degree c	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be strongly inhibit than	response to basolateral ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c strongly inhibit than response to ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c strongly inhibit than response	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be strongly inhibit at	20 degree c	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be more strongly inhibit than	response to basolateral ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be more strongly inhibit than	response	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c strongly inhibit than response to basolateral ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c more strongly inhibit than response to ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c more strongly inhibit than response	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	more strongly inhibit	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be strongly inhibit than	response to ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c inhibit than response to basolateral ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be inhibit than	response to ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be	at 20 degree c inhibit than response to ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be more strongly inhibit at	20 degree c	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be inhibit than	response	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	isc response	be inhibit than	response to basolateral ct	At 20 degrees C , the Isc response to apical CT was more strongly inhibited -LRB- 30-50 % -RRB- than the response to basolateral CT , even though translocation occurred in both cases as evidenced by the formation of A1-peptide .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	rhodamine-labeled ct-analogue	apply at	20 degree c	A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .	MESH:C027024	rhodamine	Chemical	MESH:D012211	re	Chemical
1318883	rhodamine-labeled ct-analogue	apply apically or basolaterally at	20 degree c	A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .	MESH:C027024	rhodamine	Chemical	MESH:D012211	re	Chemical
1318883	functional rhodamine-labeled ct-analogue	apply at	20 degree c	A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .	MESH:C027024	rhodamine	Chemical	MESH:D012211	re	Chemical
1318883	rhodamine-labeled ct-analogue	apply apically at	20 degree c	A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .	MESH:C027024	rhodamine	Chemical	MESH:D012211	re	Chemical
1318883	functional rhodamine-labeled ct-analogue	apply apically at	20 degree c	A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .	MESH:C027024	rhodamine	Chemical	MESH:D012211	re	Chemical
1318883	functional rhodamine-labeled ct-analogue	apply apically or basolaterally at	20 degree c	A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes , whereas movement into deeper apical structures was detected at 37 degrees C .	MESH:C027024	rhodamine	Chemical	MESH:D012211	re	Chemical
1318883	reduction	be	at 15 degree c in contrast inhibit	At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	reduction	be completely inhibit at	15 degree c	At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	reduction	be inhibit at	15 degree c	At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	reduction	be	at 15 degree c in contrast completely inhibit	At 15 degrees C , in contrast , reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide , 10 microM forskolin , and 3 mM 8Br - cAMP were intact .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to toxin action on polarize cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to apical toxin action on polarize epithelial cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to apical toxin action on polarize cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to toxin action on epithelial cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to toxin action on cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to apical toxin action	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to apical toxin action on epithelial cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to apical toxin action on cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to toxin action on polarize epithelial cell	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
1318883	result	identify	temperature-sensitive step essential to toxin action	These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
25568634	Diarrhea	be cause worldwide of	child mortality	Background : Diarrhea is a leading cause of child mortality worldwide .	MESH:D003967	diarrhea	Disease	9606	child	Species
25568634	Diarrhea	be lead cause of	child mortality	Background : Diarrhea is a leading cause of child mortality worldwide .	MESH:D003967	diarrhea	Disease	9606	child	Species
25568634	Diarrhea	be cause of	child mortality	Background : Diarrhea is a leading cause of child mortality worldwide .	MESH:D003967	diarrhea	Disease	9606	child	Species
25568634	Diarrhea	be lead cause worldwide of	child mortality	Background : Diarrhea is a leading cause of child mortality worldwide .	MESH:D003967	diarrhea	Disease	9606	child	Species
25568634	severe diarrhea	be in	child	Rotavirus is one of the most common causes of severe diarrhea and dehydration in children .	MESH:D003967	diarrhea	Disease	9606	child	Species
25568634	116 child	be with	rotavirus diarrhea	Results : 116 children with rotavirus diarrhea are included in the study .	9606	child	Species	MESH:D012400	rotavirus diarrhea	Disease
25568634	fever	be characteristic of	presentation of diarrhea	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	MESH:D003967	diarrhea	Disease
25568634	fever	be	present in patient characteristic of presentation	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	9606	patient	Species
25568634	fever	be characteristic of	clinical presentation of diarrhea	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	MESH:D003967	diarrhea	Disease
25568634	fever	be	present in patient characteristic of clinical presentation	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	9606	patient	Species
25568634	fever	be	present in patient characteristic of presentation of diarrhea	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	MESH:D003967	diarrhea	Disease
25568634	fever	be	present in patient characteristic	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	9606	patient	Species
25568634	fever	be	present in patient characteristic of clinical presentation of diarrhea	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	MESH:D003967	diarrhea	Disease
25568634	fever	be characteristic apart from	diarrhea	Apart from diarrhea , present in all patients , vomiting -LRB- 97.41 % -RRB- and fever -LRB- 43.96 % -RRB- were characteristics of the clinical presentation of the diarrhea .	MESH:D005334	fever	Disease	MESH:D003967	diarrhea	Disease
1607385	membrane-cytoskeleton	be prepare from	Dictyostelium ameba	Membrane-cytoskeletons were prepared from Dictyostelium amebas , and networks of actin and myosin II filaments were visualized on the exposed cytoplasmic surfaces of the cell membranes by fluorescence staining -LRB- Yumura , S. , and T. Kitanishi-Yumura .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	myosin filament	remain in	in 10 mm mgcl2	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D015636	mgcl2	Chemical
1607385	myosin filament	remain in	in mgcl2	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D015636	mgcl2	Chemical
1607385	myosin ii filament	remain by	contrast	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	myosin ii filament	remain in	in 10 mm mgcl2	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D015636	mgcl2	Chemical
1607385	myosin ii filament	remain in	in mgcl2	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D015636	mgcl2	Chemical
1607385	myosin filament	remain in	focus	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	myosin ii filament	remain in	focus	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	myosin filament	remain by	contrast	By contrast , myosin II filaments remained in the foci in the presence of 10 mM MgCl2 .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	phosphorylation	result in	disassembly of myosin filament	Using -LSB- gamma 32P -RSB- ATP , we found that the heavy chains of myosin II released from membrane-cytoskeletons were phosphorylated , and this phosphorylation resulted in disassembly of myosin filaments .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	phosphorylation	result in	disassembly	Using -LSB- gamma 32P -RSB- ATP , we found that the heavy chains of myosin II released from membrane-cytoskeletons were phosphorylated , and this phosphorylation resulted in disassembly of myosin filaments .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	phosphorylation	occur at	focus	Using ITP -LRB- a substrate for myosin II ATPase -RRB- and/or ATP gamma S -LRB- a substrate for myosin II heavy-chain kinase -LSB- MHCK -RSB- -RRB- , we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network , a result that suggests that MHCK was localized at the foci .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	phosphorylation	occur at	focus within actin network	Using ITP -LRB- a substrate for myosin II ATPase -RRB- and/or ATP gamma S -LRB- a substrate for myosin II heavy-chain kinase -LSB- MHCK -RSB- -RRB- , we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network , a result that suggests that MHCK was localized at the foci .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	phosphorylation	occur	result	Using ITP -LRB- a substrate for myosin II ATPase -RRB- and/or ATP gamma S -LRB- a substrate for myosin II heavy-chain kinase -LSB- MHCK -RSB- -RRB- , we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network , a result that suggests that MHCK was localized at the foci .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation to endoplasm	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation from cortical region to endoplasm	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation of myosin ii from cortical region	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation of myosin ii from region to endoplasm	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation of myosin ii	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation of myosin ii from cortical region to endoplasm	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation from cortical region	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation from region to endoplasm	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation of myosin ii from region	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation of myosin ii to endoplasm	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1607385	series	could represent	mechanism for relocation from region	This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm .	MESH:D013455	s	Chemical	MESH:D013455	s	Chemical
1577853	glut-4	be	glucose transporter isoform in tissue	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	major glucose transporter isoform	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	major facilitative glucose transporter isoform	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	major glucose transporter isoform in tissue	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	facilitative glucose transporter isoform in tissue	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	facilitative glucose transporter isoform	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	major facilitative glucose transporter isoform in tissue	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	glut-4	be	glucose transporter isoform	GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport .	6517	glut-4	Gene	MESH:D005947	glucose	Chemical
1577853	insulin	regulate glucose transport by	translocation of glut-4 from intracellular compartment to plasma membrane	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	rapid translocation of glut-4 from intracellular compartment to plasma membrane	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	translocation of glut-4 from intracellular compartment	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	rapid translocation of glut-4 to plasma membrane	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	translocation of glut-4 from compartment	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	rapid translocation of glut-4	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	rapid translocation of glut-4 from intracellular compartment	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	rapid translocation of glut-4 from compartment	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	rapid translocation of glut-4 from compartment to plasma membrane	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	translocation of glut-4	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	translocation of glut-4 from compartment to plasma membrane	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate glucose transport by	translocation of glut-4 to plasma membrane	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	6517	glut-4	Gene
1577853	insulin	regulate	glucose transport	Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane .	3630	insulin	Gene	MESH:D005947	glucose	Chemical
1577853	wild-type glut-4	be target to	intracellular compartment in cho cell	We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .	6517	glut-4	Gene	CVCL:0213	cho	CellLine
1577853	glut-4	be target to	compartment in cho cell	We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .	6517	glut-4	Gene	CVCL:0213	cho	CellLine
1577853	wild-type glut-4	be target to	compartment in cho cell	We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .	6517	glut-4	Gene	CVCL:0213	cho	CellLine
1577853	glut-4	be target to	intracellular compartment in cho cell	We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells .	6517	glut-4	Gene	CVCL:0213	cho	CellLine
25101886	Potentiator Ivacaftor	abrogate	correction	Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	Potentiator Ivacaftor	abrogate correction in	cystic fibrosis	Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .	MESH:D009584	n	Chemical	MESH:D003550	cystic fibrosis	Disease
25101886	Potentiator Ivacaftor	abrogate	pharmacological correction	Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	Potentiator Ivacaftor	abrogate	pharmacological correction of deltaf508 cftr	Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	Potentiator Ivacaftor	abrogate correction in	fibrosis	Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .	MESH:D009584	n	Chemical	MESH:D005355	fibrosis	Disease
25101886	Potentiator Ivacaftor	abrogate	correction of deltaf508 cftr	Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	mutation	be in	cf transmembrane conductance regulator	Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	fibrosis	be cause by	mutation in cf transmembrane conductance regulator	Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .	MESH:D005355	fibrosis	Disease	MESH:D003550	cf	Disease
25101886	fibrosis	be cause by	mutation	Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .	MESH:D005355	fibrosis	Disease	MESH:D009584	n	Chemical
25101886	cystic fibrosis	be cause by	mutation	Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .	MESH:D003550	cystic fibrosis	Disease	MESH:D009584	n	Chemical
25101886	cystic fibrosis	be cause by	mutation in cf transmembrane conductance regulator	Cystic Fibrosis -LRB- CF -RRB- is caused by mutations in the CF transmembrane conductance regulator -LRB- CFTR -RRB- .	MESH:D003550	cystic fibrosis	Disease	MESH:D003550	cf	Disease
25101886	important advance	be in	cf therapy	Newly developed `` correctors '' such as lumacaftor -LRB- VX-809 -RRB- that improve CFTR maturation and trafficking and `` potentiators '' such as ivacaftor -LRB- VX-770 -RRB- that enhance channel activity may provide important advances in CF therapy .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	patient	be with	deltaf508	Thus , patients with DeltaF508 will likely require treatment with both correctors and potentiators to achieve clinical benefit .	9606	patient	Species	p.508delF	deltaf508	DNAMutation
25101886	treatment	improve cftr function with	g551d mutation	In studies of human primary airway epithelial cells , we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation , consistent with clinical studies .	MESH:D009584	n	Chemical	p.G551D;RS#:75527207	g551d	ProteinMutation
25101886	treatment	improve	CFTR function in cell	In studies of human primary airway epithelial cells , we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation , consistent with clinical studies .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	treatment	improve	CFTR function	In studies of human primary airway epithelial cells , we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation , consistent with clinical studies .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	dose-dependent reversal of cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	dose-dependent reversal of cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	reversal in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 administration	cause	dose-dependent reversal of vx-809-mediated cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	dose-dependent reversal of vx-809-mediated cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	reversal of vx-809-mediated cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	reversal of cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	dose-dependent reversal of cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	dose-dependent reversal	be in	deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	p.508delF	deltaf508	DNAMutation
25101886	chronic vx-770 administration	cause reversal in	contrast	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 administration	cause	dose-dependent reversal of vx-809-mediated cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	reversal of vx-809-mediated cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	dose-dependent reversal in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 administration	cause	dose-dependent reversal of vx-809-mediated cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	reversal of vx-809-mediated cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	dose-dependent reversal of cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	dose-dependent reversal	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 administration	cause	reversal of vx-809-mediated cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	reversal of cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause reversal in	contrast	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 administration	cause	reversal of cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	reversal in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 administration	cause	reversal of vx-809-mediated cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	dose-dependent reversal of cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	dose-dependent reversal of cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	reversal in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 administration	cause	reversal of cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	dose-dependent reversal	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 administration	cause	dose-dependent reversal in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 administration	cause	reversal in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 administration	cause	dose-dependent reversal in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 administration	cause	dose-dependent reversal of vx-809-mediated cftr correction in deltaf508 culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	reversal of cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	dose-dependent reversal of vx-809-mediated cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	reversal of cftr correction	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 administration	cause	reversal of vx-809-mediated cftr correction in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 administration	cause	dose-dependent reversal in deltaf508 homozygous culture	In contrast , chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 treatment	reduce	cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	reduce	wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	also reduce	cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	reduce	mature wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	also reduce	mature wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 treatment	also reduce	function	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 treatment	reduce	function	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 treatment	reduce	wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 treatment	also reduce	cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 treatment	also reduce	mature wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 treatment	reduce	mature wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	also reduce	mature cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	reduce	cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	reduce	function	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	chronic vx-770 treatment	reduce	mature cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	also reduce	function	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	vx-770 treatment	reduce	mature cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 treatment	also reduce	wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	vx-770 treatment	also reduce	wild-type cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic vx-770 treatment	also reduce	mature cftr level	Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	chronic treatment	be with	cftr potentiator	These findings demonstrate that chronic treatment with CFTR potentiators and correctors may have unexpected effects that can not be predicted from short-term studies .	MESH:D009584	n	Chemical	MESH:D003550	cf	Disease
25101886	combine	may require	change in dosing	Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	change	be in	dosing of new potentiator compound	Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25101886	combine	may require	change	Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25568582	goal	be with	implementation of information technology	Results : There was a significant relationship between organization resource , organizational knowledge , process , management structure and values and goals with implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	impact on	implementation	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	impact on	implementation of information technology	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	have	considerable impact on implementation	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	have	considerable impact on implementation of information technology	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	have	impact on implementation of information technology	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	considerable impact on	implementation of information technology	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	have	impact on implementation	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25568582	organizational factor	considerable impact on	implementation	Conclusion : Findings showed that organizational factors had a considerable impact on implementation of information technology .	MESH:D000535	al	Chemical	9606	men	Species
25481785	targeted mutagenesis	be in	Atlantic killifish	Targeted mutagenesis of aryl hydrocarbon receptor 2a and 2b genes in Atlantic killifish -LRB- Fundulus heteroclitus -RRB- .	MESH:D009584	n	Chemical	8078	killifish	Species
25481785	more recent approach	include	mutagenesis	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	recent approach	include	targeted mutagenesis	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	more recent approach	include	targeted mutagenesis	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	gene knock-down	use	oligonucleotide	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	gene knock-down	use	random mutagenesis	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	recent approach	include	mutagenesis	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	gene knock-down	use	mutagen	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	gene knock-down	use	morpholino-modified oligonucleotide	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	loss-of-function approach	have include	gene knock-down	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	gene knock-down	use	mutagenesis	While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses , more recent approaches include targeted mutagenesis using zinc finger nuclease -LRB- ZFN -RRB- , transcription activator-like effector nuclease -LRB- TALENs -RRB- and clustered regularly interspaced short palindromic repeats -LRB- CRISPR -RRB- - Cas9 technology .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	Atlantic killifish	in 2a be	ahr2a	To facilitate evaluations of toxic mechanisms for important categories of aryl hydrocarbon pollutants , whose actions are known to be receptor mediated , we used ZFN and CRISPR-Cas9 approaches to generate aryl hydrocarbon receptor 2a -LRB- AHR2a -RRB- and AHR2b gene mutations in Atlantic killifish -LRB- Fundulus heteroclitus -RRB- embryos .	8078	killifish	Species	30517	ahr2	Gene
25481785	killifish	be	non-traditional model	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	non-traditional model for study with multiple paralog	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	particularly valuble non-traditional model for study with multiple paralog	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	valuble non-traditional model	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	valuble non-traditional model for study with multiple paralog	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	non-traditional	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	particularly valuble non-traditional model	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	non-traditional model for study with paralog	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	valuble non-traditional model for study with paralog	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	be	particularly valuble non-traditional model for study with paralog	This killifish is a particularly valuble non-traditional model for this study , with multiple paralogs of AHR whose functions are not well characterized .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	population	have evolve resistance in	addition	In addition , some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	population	have evolve	resistance to toxicant	In addition , some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	population	have evolve	resistance	In addition , some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	killifish	characterize	role of individual ahr paralog in evolve resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role in resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	characterize	role of ahr paralog in evolve resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	characterize	role of individual ahr paralog	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	characterize	role of ahr paralog in resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role of individual ahr paralog in resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role in evolve resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role of individual ahr paralog	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role of ahr paralog in resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	characterize	role of individual ahr paralog in resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role of ahr paralog in evolve resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	characterize	role in evolve resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	killifish	characterize	role in resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	ahr-null killifish	characterize	role of individual ahr paralog in evolve resistance	AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance , as well as in normal development .	8078	killifish	Species	MESH:D009584	n	Chemical
25481785	crispr-cas9 guide rna	target	region	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	crispr-cas9 guide rna	be	design	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	crispr-cas9 guide rna	target	region in exon 2	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	region	be in	exon 2 of ahr2a	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	30517	ahr2	Gene
25481785	crispr-cas9 guide rna	target	region in exon 2 of ahr2a	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	30517	ahr2	Gene
25481785	crispr-cas9 guide rna	be	subsequently design	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	crispr-cas9 guide rna	target	region in exon 2 ahr2a	Subsequently , CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b .	MESH:D009584	n	Chemical	30517	ahr2	Gene
25481785	frameshift mutation	be with	zfn	We successfully induced frameshift mutations in AHR2a exon 3 with ZFN and CRISPR-Cas9 guide RNAs , with mutation frequencies of 10 % and 16 % , respectively .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	frameshift mutation	be in	ahr2a exon 3	We successfully induced frameshift mutations in AHR2a exon 3 with ZFN and CRISPR-Cas9 guide RNAs , with mutation frequencies of 10 % and 16 % , respectively .	MESH:D009584	n	Chemical	30517	ahr2	Gene
25481785	mutation	be	induce	In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	crispr-cas9 guide rna	target	site in	In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	mutation	be induce in	ahr2b	In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .	MESH:D009584	n	Chemical	30517	ahr2	Gene
25481785	mutation	use	crispr-cas9 guide rna	In AHR2b , mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 -LRB- 17 % -RRB- and exon 3 -LRB- 63 % -RRB- .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	induce mutation at	specific locus in embryo of model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	genome-editing method	induce mutation at	locus in embryo of non-traditional model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	genome-editing method	be efficient without	detectable off-target effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	be efficient without	off-target effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	induce mutation at	specific locus in embryo	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	be	efficient	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	be efficient without	detectable off-target effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	be efficient without	detectable effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	be efficient without	detectable effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	be efficient without	detectable effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	be efficient without	off-target effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	induce mutation at	locus in embryo	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	genome-editing method	induce	mutation	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	be efficient without	effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	induce mutation at	specific locus in embryo	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	be efficient without	effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	induce mutation at	locus in embryo of model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	induce mutation at	locus in embryo of model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	genome-editing method	be efficient without	effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	induce mutation at	specific locus in embryo of non-traditional model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	genome-editing method	be efficient without	off-target effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	induce mutation at	locus in embryo of non-traditional model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	be efficient without	detectable off-target effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	induce	mutation	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	be	efficient	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	induce mutation at	locus in embryo	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	be efficient without	off-target effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	be efficient without	detectable off-target effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	target genome-editing method	induce mutation at	specific locus in embryo of model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	be efficient without	detectable effect in paralogous gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25481785	genome-editing method	induce mutation at	specific locus in embryo of non-traditional model species	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	6239	embryo	Species
25481785	target genome-editing method	be efficient without	effect in gene	Overall , our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species , without detectable off-target effects in paralogous genes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1618904	Chondrodysplasia	be in	transgenic mouse harbor	Chondrodysplasia in transgenic mice harboring a 15-amino acid deletion in the triple helical domain of pro alpha 1 -LRB- II -RRB- collagen chain .	MESH:D010009	chondrodysplasia	Disease	10090	mouse	Species
1577865	mammalian profilin	prepared from	bovine brain	We have addressed this question by directly microinjecting mammalian profilins , prepared either from an E. coli expression system or from bovine brain , into living normal rat kidney -LRB- NRK -RRB- cells .	9606	mammalian	Species	9913	bovine	Species
1560026	2,6-sialyltransferase	be	integral	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii integral membrane protein of golgi apparatus involve in sialylation of glycan	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii membrane protein of golgi apparatus involve	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii membrane protein of golgi apparatus involve in sialylation of glycan	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii integral membrane protein of golgi apparatus involve in sialylation of n-linked glycan	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii membrane protein of golgi apparatus	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii integral membrane protein	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii membrane protein	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii membrane protein of golgi apparatus involve in sialylation	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii integral membrane protein of golgi apparatus	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii membrane protein of golgi apparatus involve in sialylation of n-linked glycan	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii integral membrane protein of golgi apparatus involve in sialylation	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	beta-galactoside alpha 2,6-sialyltransferase	be	type ii integral membrane protein of golgi apparatus involve	beta-Galactoside alpha 2,6-sialyltransferase -LRB- ST -RRB- is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans .	MESH:C007816	beta-galactoside	Chemical	MESH:D009584	n	Chemical
1560026	17-residue transmembrane domain	be	sufficient	A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	transmembrane domain	confer	localization	A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	17-residue transmembrane domain	confer	localization	A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	transmembrane domain	be	sufficient	A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	chimeric protein	localized in	trans-golgi cisternae	Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	chimeric protein	localized in	cisternae	Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	protein	localized in	cisternae	Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1560026	protein	localized in	trans-golgi cisternae	Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1533397	kinesin heavy chain expression	study	phenotype of KHC null cell	To examine the function of kinesin in neurons , we sought to suppress kinesin heavy chain -LRB- KHC -RRB- expression in cultured hippocampal neurons using antisense oligonucleotides and study the phenotype of these KHC `` null '' cells .	3799	kinesin heavy chain	Gene	3799	khc	Gene
1533397	kinesin heavy chain expression	study	phenotype of KHC cell	To examine the function of kinesin in neurons , we sought to suppress kinesin heavy chain -LRB- KHC -RRB- expression in cultured hippocampal neurons using antisense oligonucleotides and study the phenotype of these KHC `` null '' cells .	3799	kinesin heavy chain	Gene	3799	khc	Gene
25530839	cognate mir-206	be	exclusively express	The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .	735281	mir	Gene	CVCL:M564	es	CellLine
25530839	mir-206	be	express	The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .	735281	mir	Gene	CVCL:M564	es	CellLine
25530839	cognate mir-206	be	express	The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .	735281	mir	Gene	CVCL:M564	es	CellLine
25530839	mir-206	be	exclusively express	The two miR-1 / 133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle , while the cognate miR-206 / 133b cluster is exclusively expressed in skeletal muscle .	735281	mir	Gene	CVCL:M564	es	CellLine
25530839	mir-206	contain	seed sequence important for mirna-target recognition	Similarly , miR-1 and miR-206 are structurally related and contain identical seed sequences important for miRNA-target recognition .	735281	mir	Gene	735281	mir	Gene
25530839	mir-206	contain	identical seed sequence important for mirna-target recognition	Similarly , miR-1 and miR-206 are structurally related and contain identical seed sequences important for miRNA-target recognition .	735281	mir	Gene	735281	mir	Gene
1577858	c2 mouse myoblast	be transfect with	human beta	C2 mouse myoblasts were transfected with the human beta - and gamma-actin genes .	10090	mouse	Species	9606	human	Species
1315319	h36-alpha 7 chain	be associate with	integrin beta 1	Immunoblots and immunofluorescence demonstrate that the H36-alpha 7 chain is associated with integrin beta 1 .	81008	h36-alpha 7	Gene	24511	integrin beta 1	Gene
25530820	mlh1 splice site mutation	be in	cell derive from Lynch syndrome patient	Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .	4292	mlh1	Gene	MESH:D003123	lynch syndrome	Disease
25530820	nucleosome positioning	be unaltered at	mlh1 splice site mutation in cell derive from Lynch syndrome patient	Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	nucleosome positioning	be unaltered at	mlh1 splice site mutation	Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .	MESH:D002244	c	Chemical	4292	mlh1	Gene
25530820	nucleosome positioning	be unaltered at	mlh1 splice site mutation in cell derive	Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .	MESH:D002244	c	Chemical	4292	mlh1	Gene
25530820	nucleosome positioning	be unaltered at	mlh1 splice site mutation in cell	Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients .	MESH:D002244	c	Chemical	4292	mlh1	Gene
25530820	nucleosome	be important for	splice site recognition	Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	background splicing	couple with	transcription	Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	background splicing	be	more efficient	Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	background splicing	be	efficient	Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Lynch syndrome	be	familial cancer syndrome	Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 -LRB- MLH1 -RRB- gene .	MESH:D003123	lynch syndrome	Disease	MESH:D009369	cancer	Disease
25530820	Lynch syndrome	be	cancer syndrome	Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 -LRB- MLH1 -RRB- gene .	MESH:D003123	lynch syndrome	Disease	MESH:D009369	cancer	Disease
25530820	autosomal dominant inheritance	be in	mutl homolog 1	Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 -LRB- MLH1 -RRB- gene .	MESH:D002244	c	Chemical	4292	mutl homolog 1	Gene
25530820	mlh1 splice site mutation	be in	Lynch syndrome case	To better understand the role of nucleosomes in splicing , we used MLH1 splice site mutations in Lynch syndrome cases as a model to investigate if abnormal splicing was associated with altered nucleosome positioning at exon-intron boundaries .	4292	mlh1	Gene	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation in lymphoblastoid cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	splice site mutation in lymphoblastoid cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation in lymphoblastoid cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation in lymphoblastoid cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation in cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	splice site mutation	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation in lymphoblastoid cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	splice site mutation in cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	splice site mutation in lymphoblastoid cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation in cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation in cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation in cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	heterozygous splice site mutation	be in	lymphoblastoid cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation in lymphoblastoid cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation in lymphoblastoid cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation in lymphoblastoid cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation in cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning of	nucleosome	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation in cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation in lymphoblastoid cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation in cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation in lymphoblastoid cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	positioning around	splice site mutation in cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	allele-specific positioning of	nucleosome	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	splice site mutation	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	allele-specific positioning around	heterozygous splice site mutation in cell line derive from six Lynch syndrome patient	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	Methylome sequencing	positioning around	heterozygous splice site mutation in cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	splice site mutation in cell line	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	Methylome sequencing	positioning around	splice site mutation in lymphoblastoid cell line derive	Findings Nucleosome Occupancy and Methylome sequencing -LRB- NOMe-seq -RRB- was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines -LRB- LCLs -RRB- derived from six Lynch syndrome patients .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution nucleosome mapping	reveal	high level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	high-resolution nucleosome mapping	reveal	level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific mapping	reveal	level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	nucleosome mapping	reveal	level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution nucleosome mapping	reveal	level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution mapping	reveal	high level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific nucleosome mapping	reveal	high level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	high-resolution nucleosome mapping	reveal	high level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific nucleosome mapping	reveal	level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific mapping	reveal	high level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific nucleosome mapping	reveal	level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution mapping	reveal	high level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	high-resolution nucleosome mapping	reveal	high level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution nucleosome mapping	reveal	high level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	nucleosome mapping	reveal	high level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific nucleosome mapping	reveal	high level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution mapping	reveal	level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution nucleosome mapping	reveal	level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	high-resolution nucleosome mapping	reveal	level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific mapping	reveal	high level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific high-resolution mapping	reveal	level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	nucleosome mapping	reveal	high level of nucleosome across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	nucleosome mapping	reveal	level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	allele-specific mapping	reveal	level across region examine	Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	conclusion nucleosome	be	enrich at mlh1 exon in lcl	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	4292	mlh1	Gene
25530820	conclusion nucleosome	be enrich in	lcl derive	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	conclusion nucleosome	be	enrich at mlh1 exon in lcl derive	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	4292	mlh1	Gene
25530820	conclusion nucleosome	be enrich at	mlh1 exon	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	4292	mlh1	Gene
25530820	conclusion nucleosome	be	enrich	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
25530820	conclusion nucleosome	be enrich in	lcl derive from Lynch syndrome patient	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	conclusion nucleosome	be	enrich at mlh1 exon in lcl derive from Lynch syndrome patient	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	MESH:D003123	lynch syndrome	Disease
25530820	conclusion nucleosome	be enrich in	lcl	Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients , and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations .	MESH:D002244	c	Chemical	MESH:D002244	c	Chemical
1607386	beta-galactosidase fusion protein	localize phospholipid binding domain in	nh2-terminal half	We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail .	2720	beta-galactosidase	Gene	MESH:D000641	nh2	Chemical
1607386	beta-galactosidase fusion protein	localize	phospholipid binding domain of acanthamoeba myosin ic	We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail .	2720	beta-galactosidase	Gene	4641	myosin ic	Gene
1607386	beta-galactosidase fusion protein	localize phospholipid binding domain in	nh2-terminal half of tail	We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail .	2720	beta-galactosidase	Gene	MESH:D000641	nh2	Chemical
1607386	atp-insensitive actin binding site	be contain	previously show for acanthamoeba myosin ia	We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .	MESH:D000255	atp	Chemical	MESH:D015823	acanthamoeba myosin ia	Disease
1607386	atp-insensitive actin binding site	be contain in	cooh-terminal 30 kd	We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .	MESH:D000255	atp	Chemical	MESH:C102887	cooh	Chemical
1607386	atp-insensitive actin binding site	previously show for	acanthamoeba myosin ia	We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .	MESH:D000255	atp	Chemical	MESH:D015823	acanthamoeba myosin ia	Disease
1607386	atp-insensitive actin binding site	be contain in	cooh-terminal 30 kd of tail	We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .	MESH:D000255	atp	Chemical	MESH:C102887	cooh	Chemical
1607386	atp-insensitive actin binding site	be contain	show for acanthamoeba myosin ia	We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .	MESH:D000255	atp	Chemical	MESH:D015823	acanthamoeba myosin ia	Disease
1607386	atp-insensitive actin binding site	show for	acanthamoeba myosin ia	We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA .	MESH:D000255	atp	Chemical	MESH:D015823	acanthamoeba myosin ia	Disease
1352300	BFA	abolish	apical targeting of dppiv	BFA was found to abolish the apical targeting of DPPIV .	MESH:C524118	bfa	Chemical	MESH:D018819	dppiv	Chemical
1352300	BFA	abolish	targeting of dppiv	BFA was found to abolish the apical targeting of DPPIV .	MESH:C524118	bfa	Chemical	MESH:D018819	dppiv	Chemical
1352300	dppiv	be	transcytose back to apical domain after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be	transcytose back to domain after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be transcytose back after	BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be transcytose back after	BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be transcytose after	BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be	transcytose back to domain after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be transcytose after	BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be	transcytose back to domain only after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be transcytose after	only BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be transcytose back after	only BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be transcytose after	only BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	dppiv	be	transcytose back to apical domain only after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be transcytose back after	only BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be	transcytose back to domain only after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be	transcytose back to apical domain only after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1352300	mistargeted dppiv	be	transcytose back to apical domain after BFA withdrawal	The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal .	MESH:D018819	dppiv	Chemical	MESH:C524118	bfa	Chemical
1374069	anti-beta 1 antibody	binding to	fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	anti-beta 1 antibody	binding of	u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	binding of	myelomonocytic u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	binding of	myelomonocytic u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	strongly enhance	binding of u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	strongly enhance	binding of myelomonocytic u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	strongly enhance	binding to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	anti-beta 1 antibody	strongly enhance	binding of u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	enhance	binding to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	certain anti-beta 1 antibody	binding of	u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	strongly enhance	binding of myelomonocytic u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	enhance	binding of myelomonocytic u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	strongly enhance	binding of u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	enhance	binding of myelomonocytic u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	binding to	fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	certain anti-beta 1 antibody	enhance	binding to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	certain anti-beta 1 antibody	enhance	binding of u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	certain anti-beta 1 antibody	enhance	binding of u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	enhance	binding of myelomonocytic u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	strongly enhance	binding of myelomonocytic u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	enhance	binding of u-937 cell to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	strongly enhance	binding of myelomonocytic u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	enhance	binding of u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	enhance	binding of myelomonocytic u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	anti-beta 1 antibody	strongly enhance	binding to fibronectin	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	certain anti-beta 1 antibody	strongly enhance	binding of u-937 cell	We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin .	3779	beta 1	Gene	CVCL:0007	u-937	CellLine
1374069	beta 1-mediated effect	involve	vla-4	This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	beta 1-mediated regulatory effect	involve	vla-5 fibronectin receptor	This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	beta 1-mediated effect	involve	vla-5 fibronectin receptor	This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .	3779	beta 1	Gene	2335	fibronectin	Gene
1374069	beta 1-mediated regulatory effect	involve	vla-4	This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to recombinant form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover induce	binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to recombinant soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover also induce	binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover induce	binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to recombinant form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to recombinant form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to recombinant soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to recombinant soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to recombinant soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover also induce	binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover induce	binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to recombinant form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover also induce	binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	binding to recombinant soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	binding to form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	induce	vla-4-mediated binding to soluble form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	binding to recombinant form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	moreover also induce	binding to recombinant form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	7412	vcam-1	Gene
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding to form	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	also induce	vla-4-mediated binding	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to soluble form of its endothelial cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover induce	vla-4-mediated binding to soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	anti-beta 1 mab	moreover also induce	vla-4-mediated binding to recombinant soluble form of its cell ligand vcam-1	Moreover , anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1 .	3779	beta 1	Gene	MESH:D039041	vla-4	Chemical
1374069	vla-4 interaction	be with	fibronectin	Non - activated peripheral blood T lymphocytes , unable to mediate VLA-4 interactions with fibronectin or VCAM-1 , acquired the ability to bind these ligands in the presence of anti-beta 1 mAb .	MESH:D039041	vla-4	Chemical	2335	fibronectin	Gene
25568626	patient	be with	postoperative pulmonary thromboembolism	Objective : Our objective is to show the number of patients with postoperative pulmonary thromboembolism -LRB- PPTE -RRB- treated in Intensive care unit of Clinic for pulmonary diseases an TB `` Podhrastovi '' in three-year period : from June 1 , 2011 - June 1 , 2014 and to indicate the importance of various surgical operations in the development of pulmonary thromboembolism -LRB- PTE -RRB- .	9606	patient	Species	MESH:D011655	pulmonary thromboembolism	Disease
25568626	patient	be with	ppte treat in intensive care unit of Clinic	Material and methods : This is the retrospective study which shows the number of patients with PPTE treated in Intensive care unit of Clinic for pulmonary diseases an TB `` Podhrastovi '' in three-year period : from 01.06.2011.-01.06 .2014 .	9606	patient	Species	MESH:D011655	pte	Disease
25568626	patient	of cent be	massiveness with embolus	It represents the number of these patients , per cent of patients with PPTE of total patients with PTE , age and sex of patients , type of surgery , period expressed in days from surgery to diagnosis of PTE , presence of deep venous thrombosis -LRB- DVT -RRB- of lower extremities , massiveness of PPTE e.g. level of pulmonary artery with embolus .	9606	patient	Species	MESH:D004617	embolus	Disease
25568626	patient	be with	ppte of total patient	It represents the number of these patients , per cent of patients with PPTE of total patients with PTE , age and sex of patients , type of surgery , period expressed in days from surgery to diagnosis of PTE , presence of deep venous thrombosis -LRB- DVT -RRB- of lower extremities , massiveness of PPTE e.g. level of pulmonary artery with embolus .	9606	patient	Species	MESH:D011655	pte	Disease
25568626	total patient	be with	pte of patient	It represents the number of these patients , per cent of patients with PPTE of total patients with PTE , age and sex of patients , type of surgery , period expressed in days from surgery to diagnosis of PTE , presence of deep venous thrombosis -LRB- DVT -RRB- of lower extremities , massiveness of PPTE e.g. level of pulmonary artery with embolus .	9606	patient	Species	MESH:D011655	pte	Disease
25568626	232 patient	be with	pte	Results : In three-year period 232 patients with PTE were treated in Intensive care unit of Clinic `` Podhrastovi '' .	9606	patient	Species	MESH:D011655	pte	Disease
25568626	ppte	develop in	15 patient	PPTE developed in 15 patients with abdominal , 11 with urologic , 8 with gynecologic , 15 with orthopedic , 4 with cardiologic , 2 with vascular , 3 with neurosurgical , 1 with glandular and 1 with orl operations .	MESH:D011655	pte	Disease	9606	patient	Species
25568626	ppte	develop in	15 patient with abdominal	PPTE developed in 15 patients with abdominal , 11 with urologic , 8 with gynecologic , 15 with orthopedic , 4 with cardiologic , 2 with vascular , 3 with neurosurgical , 1 with glandular and 1 with orl operations .	MESH:D011655	pte	Disease	9606	patient	Species
25568626	patient	have	acute dvt	Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .	9606	patient	Species	MESH:D020246	dvt	Disease
25568626	patient	have	dvt	Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .	9606	patient	Species	MESH:D020246	dvt	Disease
25568626	two patient	have	acute dvt	Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .	9606	patient	Species	MESH:D020246	dvt	Disease
25568626	two patient	have	dvt	Only two patients had acute DVT after operation -LRB- one man and one woman -RRB- , and five had amnesias of previous DVT or PTE .	9606	patient	Species	MESH:D020246	dvt	Disease
25568626	patient	be with	anamnesis of previous DVT	There is great significance of anticoagulant prophylaxis before surgery even in patients with no anamnesis of previous DVT or PTE .	9606	patient	Species	MESH:D020246	dvt	Disease
1577860	bip	form complex in	c2 muscle cell	BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .	3309	bip	Gene	CVCL:0529	c2	CellLine
1577860	bip	form complex in	cos cell	BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .	3309	bip	Gene	CVCL:0222	cos	CellLine
1577860	bip	form complex with	subunit of acetylcholine receptor	BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .	3309	bip	Gene	MESH:D000109	acetylcholine	Chemical
1577860	bip	form complex in	transfect cos cell	BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .	3309	bip	Gene	CVCL:0222	cos	CellLine
1577860	bip	form complex with	unassembled subunit of acetylcholine receptor	BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells .	3309	bip	Gene	MESH:D000109	acetylcholine	Chemical
25568630	patient	be with	chronic kidney disease	Background and aim : Nutrition is a key factor in the treatment of patients with chronic kidney disease because kidney burden decrease causes uremic reduction and its side effects .	9606	patient	Species	MESH:D007674	kidney	Disease
25568630	creatinine amount	be in	patient	There was a significant difference between the creatinine amount in patients before and after of training -LRB- p < = 0.01 -RRB- but no meaningful difference was observed between the BUN amount before and after of training -LRB- p < = 0.031 -RRB- .	MESH:D002857	cr	Chemical	9606	patient	Species
25568633	Health Management Musters student	be in	Canakkale Onsekiz Mart University Health Sciences Institute	Methods : This cross-sectional study was conducted on Health Management Musters students -LRB- N = 96 -RRB- in Canakkale Onsekiz Mart University Health Sciences Institute , May-June 2014 .	9606	men	Species	5414	mart	Gene
25568633	32 people	be in	group at risk of depression	In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .	9606	people	Species	MESH:D003866	depression	Disease
25568633	32 people	be in	in we study group group at risk of depression	In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .	9606	people	Species	MESH:D003866	depression	Disease
25568633	people	be in	in we study group group at risk of depression	In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .	9606	people	Species	MESH:D003866	depression	Disease
25568633	people	be in	group at risk of depression	In our study group according to GHQ scale 32 people -LRB- 55.2 % -RRB- were in the group at risk of depression .	9606	people	Species	MESH:D003866	depression	Disease
1577868	ncam	promote neurite outgrowth via	activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	directly promote neurite outgrowth via	g-protein-dependent activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	directly promote neurite outgrowth via	g-protein-dependent activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	directly promote neurite outgrowth from	pc12 cell	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	CVCL:0481	pc12	CellLine
1577868	n-cadherin	promote neurite outgrowth via	activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	promote neurite outgrowth via	g-protein-dependent activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	directly promote neurite outgrowth via	activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	directly promote neurite outgrowth via	activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	directly promote neurite outgrowth from	pc12 cell	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	CVCL:0481	pc12	CellLine
1577868	ncam	promote neurite outgrowth via	g-protein-dependent activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	promote neurite outgrowth via	g-protein-dependent activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	directly promote neurite outgrowth via	g-protein-dependent activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	directly promote neurite outgrowth via	g-protein-dependent activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	promote neurite outgrowth from	pc12 cell	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	CVCL:0481	pc12	CellLine
1577868	ncam	promote neurite outgrowth via	activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	promote neurite outgrowth via	g-protein-dependent activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	directly promote neurite outgrowth via	activation of neuronal calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1577868	n-cadherin	promote neurite outgrowth from	pc12 cell	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	CVCL:0481	pc12	CellLine
1577868	n-cadherin	promote neurite outgrowth via	activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	83501	n-cadherin	Gene	MESH:D002118	calcium	Chemical
1577868	ncam	directly promote neurite outgrowth via	activation of calcium channel	NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels .	4684	ncam	Gene	MESH:D002118	calcium	Chemical
1560029	tag	be sonicate with	dioleoyl phosphatidylcholine	High stability was achieved only when the TAG were sonicated with both oil body PL -LRB- or dioleoyl phosphatidylcholine -RRB- and oleosins of proportions similar to or higher than those in the native oil bodies .	MESH:D014280	tag	Chemical	MESH:C017251	dioleoyl phosphatidylcholine	Chemical
23910958	t-cell lymphoma	be express in	certain b	The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .	MESH:D008223	lymphoma	Disease	MESH:D002244	c	Chemical
23910958	bcl6 gene	be involve with	chromosomal rearrangement	The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .	12053	bcl6	Gene	MESH:D002244	c	Chemical
23910958	bcl6 gene	be involve with	rearrangement	The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .	12053	bcl6	Gene	MESH:D009584	n	Chemical
23910958	bcl6 gene	be	involve	The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .	12053	bcl6	Gene	MESH:D009584	n	Chemical
23910958	t-cell human lymphoma	be express in	certain b	The BCL6 gene , which is expressed in certain B - and T-cell human lymphomas , is involved with chromosomal rearrangements and mutations in a number of these neoplasms .	MESH:D008223	lymphoma	Disease	MESH:D002244	c	Chemical
23910958	lymphomagenesis	be believe	evolve through multi-step accumulation of genetic alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	evolve through	accumulation of genetic alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	be believe	evolve through multi-step accumulation of genetic alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	evolve through	multi-step accumulation of alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	evolve through	accumulation	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D002244	c	Chemical
23910958	genetic alteration	be in	tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	10116	rat	Species	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	be believe	evolve through accumulation of genetic alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	evolve through	accumulation of alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	evolve through	multi-step accumulation of genetic alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	evolve through	multi-step accumulation	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D002244	c	Chemical
23910958	lymphomagenesis	evolve through	multi-step accumulation of alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	be believe	evolve through accumulation	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D002244	c	Chemical
23910958	lymphomagenesis	be believe	evolve through accumulation of alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	evolve through	accumulation of genetic alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	be believe	evolve through accumulation of genetic alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	be believe	evolve through multi-step accumulation of alteration	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	10116	rat	Species
23910958	lymphomagenesis	be believe	evolve through accumulation of alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	evolve through	accumulation of alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	evolve through	multi-step accumulation of genetic alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	be believe	evolve through multi-step accumulation of alteration in tumor	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D009369	tumor	Disease
23910958	lymphomagenesis	be believe	evolve through multi-step accumulation	Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors .	MESH:D008223	lymphoma	Disease	MESH:D002244	c	Chemical
23910958	retroviral insertional mutagenesis	be in	transgenic mouse express	We used retroviral insertional mutagenesis in transgenic mice expressing the human BCL6 transgene in order to identify genes that cooperate with BCL6 during lymphomatous transformation .	31931	retroviral	Species	10090	mouse	Species
23910958	lymphoma	be in	retroviral-injected non-transgenic control	We now report three newly identified cooperating genes : GFI1B , EVI5 , and MYB : that we identified in the lymphomas of retroviral-injected BCL6 transgenic mice -LRB- but not in retroviral-injected non-transgenic controls -RRB- ; mRNA and protein expression of GFI1B and EVI5 were decreased in the murine tumors , whereas MYB mRNA and protein expression were increased or decreased .	MESH:D008223	lymphoma	Disease	31931	retroviral	Species
23910958	finding	correlate with	protein expression in human lymphoma	These findings correlated with protein expression in human lymphomas , both B - and T-cell .	MESH:D009584	n	Chemical	MESH:D008223	lymphoma	Disease
23910958	finding	correlate with	protein expression	These findings correlated with protein expression in human lymphomas , both B - and T-cell .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
23910958	protein expression	be in	human lymphoma	These findings correlated with protein expression in human lymphomas , both B - and T-cell .	MESH:D009584	n	Chemical	MESH:D008223	lymphoma	Disease
23910958	finding	correlate with	protein expression in lymphoma	These findings correlated with protein expression in human lymphomas , both B - and T-cell .	MESH:D009584	n	Chemical	MESH:D008223	lymphoma	Disease
23910958	alteration	specific to	neoplasm	Improved therapy of lymphomas may necessitate the development of combinations of drugs that target the alterations specific to each neoplasm .	10116	rat	Species	MESH:D009369	neoplasm	Disease
25568631	intrauterine insemination outcome	be in	couple with male factor	Objective : To exam semen parameters in predicting intrauterine insemination -LRB- IUI -RRB- outcomes in couples with male factor .		intrauterine	Chemical	9606	male	Species
25568631	infertile couple	be with	male factor	Conclusions : The initial total progressive sperm count lower than 5 * 106 means the poor outcome of IUI in the infertile couples with male factor .	MESH:D007246	infertile	Disease	9606	male	Species
25568577	preoperative kidney tumor embolization	be procedure for	therapy in kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	preoperative kidney tumor embolization	be standard procedure for	therapy in kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	kidney tumor embolization	be standard procedure for	therapy in advanced kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	kidney tumor embolization	be procedure for	therapy in kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	preoperative kidney tumor embolization	be procedure for	therapy in advanced kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	preoperative kidney tumor embolization	be standard procedure for	therapy in advanced kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	kidney tumor embolization	be standard procedure for	therapy in kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	kidney tumor embolization	be procedure for	therapy in advanced kidney cancer	ABSTRACT Introduction : Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer .	MESH:D004617	embolization	Disease	MESH:D007680	kidney cancer	Disease
25568577	patient	be compare with	group of 51 patient from Urology Sarajevo	All patients with preoperative embolization were compared with the group of 51 patients from Urology Sarajevo , who underwent nephrectomy without preoperative embolization .	9606	patient	Species	9606	patient	Species
25568577	patient	be compare with	group of 51 patient	All patients with preoperative embolization were compared with the group of 51 patients from Urology Sarajevo , who underwent nephrectomy without preoperative embolization .	9606	patient	Species	9606	patient	Species
1374068	1-d sds-page	be insufficient for	definitive nf kinetics in mouse optic system	We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .	MESH:C032259	sds	Chemical	10090	mouse	Species
1374068	1-d sds-page	be insufficient for	nf kinetics in mouse optic system	We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .	MESH:C032259	sds	Chemical	10090	mouse	Species
1374068	1-d sds-page	be insufficient for	definitive nf kinetics in mouse system	We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .	MESH:C032259	sds	Chemical	10090	mouse	Species
1374068	1-d sds-page	be insufficient for	nf kinetics in mouse system	We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system .	MESH:C032259	sds	Chemical	10090	mouse	Species
1315315	synthesize protein	be in	endoplasmic reticulum	Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	Semliki Forest virus spike glycoprotein e1	be	study in infected	Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	Semliki Forest virus glycoprotein e1	be	study in infected	Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	synthesize Semliki Forest virus spike glycoprotein e1	be	study in infected	Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	synthesize Semliki Forest virus glycoprotein e1	be	study in infected	Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	misfolded protein	aggregate in	min	Misfolded proteins aggregated in less than 1 min after release from polysomes and aberrant interchain disulfide bonds were formed immediately .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	protein	aggregate in	min	Misfolded proteins aggregated in less than 1 min after release from polysomes and aberrant interchain disulfide bonds were formed immediately .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	formation	be	nonspecific	This indicated that the formation of complexes was nonspecific , random , and not restricted to products from single polysomes .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	bip	be	associate noncovalently	BiP was associated noncovalently with the aggregates and with some of the nonaggregated products .	3309	bip	Gene	MESH:D009584	n	Chemical
1315315	aggregation	poor solubility of	fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	poor solubility of	incompletely fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	reflect	poor solubility of polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	poor solubility of	polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	reflect	solubility of fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	reflect	solubility of polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	reflect	poor solubility of fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	reflect	poor solubility of incompletely fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	solubility of	polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	reflect	solubility of incompletely fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	solubility of	incompletely fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1315315	aggregation	solubility of	fold polypeptide chain	We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1607387	gas2	be conserve during	evolution with apparent molecular mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be conserve during	evolution with apparent mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be well conserve during	evolution with apparent molecular mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be well conserve during	evolution with same apparent molecular mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be conserve during	evolution with same apparent molecular mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be well conserve during	evolution with same apparent mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be well conserve during	evolution with apparent mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2	be conserve during	evolution with same apparent mass between mouse	Gas2 is well conserved during the evolution with the same apparent molecular mass -LRB- 36 kD -RRB- between mouse and human .	14453	gas2	Gene	10090	mouse	Species
1607387	gas2 expression	be in	none of analyze oncogene-transformed nih 3t3 cell line	In none of the analyzed oncogene-transformed NIH 3T3 cell lines was Gas2 expression induced under serum starvation .	14453	gas2	Gene	CVCL:0594	nih 3t3	CellLine
1577869	edta	first induce	dissolution of ECC basement membrane	First , low temperature and EDTA induced the dissolution of ECC basement membranes and released approximately 80 % of total laminin from the EHS basement membrane .	MESH:D004492	edta	Chemical	CVCL:M564	ecc	CellLine
1577869	edta	induce	dissolution of ECC basement membrane	First , low temperature and EDTA induced the dissolution of ECC basement membranes and released approximately 80 % of total laminin from the EHS basement membrane .	MESH:D004492	edta	Chemical	CVCL:M564	ecc	CellLine
1577862	Neurolin	glycoprotein on	grow retinal axon in goldfish visual system	Neurolin , a cell surface glycoprotein on growing retinal axons in the goldfish visual system , is reexpressed during retinal axonal regeneration .	30194	neurolin	Gene	7957	goldfish	Species
1577862	nh2-terminal amino acid sequence	have	homology recently describe in chicken	The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .	MESH:D000641	nh2	Chemical	9031	chicken	Species
1577862	nh2-terminal amino acid sequence	have	homology to cell adhesion molecule recently describe in chicken	The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .	MESH:D000641	nh2	Chemical	9031	chicken	Species
1577862	nh2-terminal amino acid sequence	have	homology to cell adhesion molecule describe in chicken	The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .	MESH:D000641	nh2	Chemical	9031	chicken	Species
1577862	nh2-terminal amino acid sequence	have	homology describe in chicken	The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken .	MESH:D000641	nh2	Chemical	9031	chicken	Species
1533642	mouse ft210 cell line	be	cdc2 mutant	The mouse FT210 cell line is a temperature-sensitive cdc2 mutant .	10090	mouse	Species	12534	cdc2	Gene
1533642	mouse ft210 cell line	be	temperature-sensitive cdc2 mutant	The mouse FT210 cell line is a temperature-sensitive cdc2 mutant .	10090	mouse	Species	12534	cdc2	Gene
1533642	mouse cell	possess	at least two cdc2	We show that mouse cells possess at least two cdc2 - related gene products which form cell cycle regulated histone H1 kinases and we propose that the murine homolog of yeast p34cdc/CDC28 is essential only during the G2-to-M transition in FT210 cells .	10090	mouse	Species	12534	cdc2	Gene
1577872	Dystrophin	colocalize in	subsarcolemmal domain in mammalian muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	distinct domain in mammalian muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	distinct subsarcolemmal domain in mammalian muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	domain in mammalian muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	distinct domain in mammalian skeletal muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	distinct subsarcolemmal domain in mammalian skeletal muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	subsarcolemmal domain in mammalian skeletal muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
1577872	Dystrophin	colocalize in	domain in mammalian skeletal muscle	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle .	1756	dystrophin	Gene	9606	mammalian	Species
25568576	pain	be in	Children of 99mTc mdp bone scintigraphy	Back Pain in Children and Diagnostic Value of 99mTc MDP Bone Scintigraphy .	MESH:D010146	pain	Disease	1800	mdp	Gene
25568576	child	be with	back pain	ABSTRACT Aim : The aim of our study is to assess the diagnostic value of Technituim-99m-Methyle diphosphonate -LRB- 99mTc-MDP -RRB- Bone scintigraphy in the assessment of children with back pain .	9606	child	Species	MESH:D010146	pain	Disease
25568576	68 child	complain of	pain	Methods : Included in this retrospective study were 68 child referred to us complaining of back pain -LRB- mean age of 13 + 2 -RRB- .	9606	child	Species	MESH:D010146	pain	Disease
25568576	68 child	complain of	back pain	Methods : Included in this retrospective study were 68 child referred to us complaining of back pain -LRB- mean age of 13 + 2 -RRB- .	9606	child	Species	MESH:D010146	pain	Disease
25568576	necrosis	be in	femoral head epiphysis	Scans findings were suggestive of spondylolysis -LRB- n = 4 -RRB- ; malignancy including primary tumors and metastases -LRB- n = 3 -RRB- ; infection including osteomyelitis and discitis -LRB- n = 3 -RRB- ; sacroiliitis -LRB- n = 2 -RRB- ; benign tumors -LRB- n = 2 -RRB- ; pseudo fractures in ribs -LRB- n = 1 -RRB- ; necrosis in femoral head epiphysis -LRB- n = 1 -RRB- and nonskeletal-renal retention due to hydronephrosis -LRB- n = 1 -RRB- .	MESH:D009336	necrosis	Disease	MESH:D060048	femoral head epiphysis	Disease
1607388	kinesin heavy chain	show distribution after	expression in cv-1 cell	After transient expression in CV-1 cells , the kinesin heavy chain showed both a diffuse distribution and a filamentous staining pattern that coaligned with microtubules but not vimentin intermediate filaments .	3799	kinesin heavy chain	Gene	CVCL:0229	cv-1	CellLine
24548058	conclusion Midazolam	experience degradation throughout	120 day of EMS deployment in high-heat environment	Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .	MESH:D008874	midazolam	Chemical	MESH:D004630	ems	Disease
24548058	diazepam	experience degradation throughout	120 day of EMS deployment in environment	Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .	MESH:D003975	diazepam	Chemical	MESH:D004630	ems	Disease
24548058	conclusion Midazolam	experience degradation throughout	120 day of EMS deployment in environment	Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .	MESH:D008874	midazolam	Chemical	MESH:D004630	ems	Disease
24548058	diazepam	experience degradation throughout	120 day of EMS deployment	Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .	MESH:D003975	diazepam	Chemical	MESH:D004630	ems	Disease
24548058	diazepam	experience degradation throughout	120 day of EMS deployment in high-heat environment	Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .	MESH:D003975	diazepam	Chemical	MESH:D004630	ems	Disease
24548058	conclusion Midazolam	experience degradation throughout	120 day of EMS deployment	Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments .	MESH:D008874	midazolam	Chemical	MESH:D004630	ems	Disease
25439054	cocaine	be in	rhesus monkey	A generalized matching law analysis of cocaine vs. food choice in rhesus monkeys : Effects of candidate ` agonist-based ' medications on sensitivity to reinforcement .	MESH:D003042	cocaine	Chemical	MESH:D008992	monkey	Disease
25439054	cocaine vs. food choice procedure	be in	rhesus monkey	Background We have previously demonstrated reductions in cocaine choice produced by either continuous 14-day phendimetrazine and D-amphetamine treatment or removing cocaine availability under a cocaine vs. food choice procedure in rhesus monkeys .	MESH:D003042	cocaine	Chemical	MESH:D008992	monkey	Disease
25439054	cocaine choice dose-effect function	be in	individual monkey	Results GML models provided an excellent fit of the cocaine choice dose-effect functions in individual monkeys .	MESH:D003042	cocaine	Chemical	MESH:D008992	monkey	Disease
1572892	yeast s. cerevisiae	from protein be	nbp	These proteins are recognized by antibodies raised against a previously identified NLS-binding protein -LRB- NBP -RRB- from the yeast S. cerevisiae .	4932	s. cerevisiae	Species	MESH:C540573	nbp	Chemical
1315317	anti-il-8 antiserum	be use in	combination with paf receptor antagonist	When the anti-IL-8 antiserum was used in combination with a PAF receptor antagonist , neutrophil migration across cytokine-pretreated monolayers of EC was completely prevented .	3576	il-8	Gene	9768	paf	Gene
1315317	anti-il-8 antiserum	be	when use in combination with paf receptor antagonist	When the anti-IL-8 antiserum was used in combination with a PAF receptor antagonist , neutrophil migration across cytokine-pretreated monolayers of EC was completely prevented .	3576	il-8	Gene	9768	paf	Gene
1315317	human neutrophil	be	activate by paf during in diapedesis in between ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by paf during in diapedesis in between cytokine-stimulated ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by paf during diapedesis	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by ec-associated paf during diapedesis in between ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by ec-associated paf during in diapedesis	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by paf during in diapedesis	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by ec-associated paf during in diapedesis in between cytokine-stimulated ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be activate by	paf	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by ec-associated paf during in diapedesis in between ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by ec-associated paf during diapedesis in between cytokine-stimulated ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be activate by	ec-associated paf	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by paf during diapedesis in between ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by paf during diapedesis in between cytokine-stimulated ec	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1315317	human neutrophil	be	activate by ec-associated paf during diapedesis	Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC .	9606	human	Species	9768	paf	Gene
1607384	amppnp binding	cause	transition to 10s myosin conformation	In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .	MESH:D000266	amppnp	Chemical	79784	myosin	Gene
1607384	amppnp binding	cause	transition to 10s myosin conformation at site	In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .	MESH:D000266	amppnp	Chemical	79784	myosin	Gene
1607384	amppnp binding	cause	transition to 10s myosin conformation at active site	In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .	MESH:D000266	amppnp	Chemical	79784	myosin	Gene
1607384	amppnp binding	cause	transition to soluble 10s myosin conformation at active site	In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .	MESH:D000266	amppnp	Chemical	79784	myosin	Gene
1607384	amppnp binding	cause	transition to soluble 10s myosin conformation at site	In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .	MESH:D000266	amppnp	Chemical	79784	myosin	Gene
1607384	amppnp binding	cause	transition to soluble 10s myosin conformation	In physiologically relevant buffers , AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites .	MESH:D000266	amppnp	Chemical	79784	myosin	Gene
1607384	myosin assembly	cause rearrangement into	actomyosin fiber compose	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	cause rearrangement into	actomyosin fiber	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	furthermore cause rearrangement into	actomyosin fiber compose	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	furthermore cause rearrangement into	actomyosin fiber compose of f-actin	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	cause rearrangement into	actomyosin fiber compose of f-actin	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	furthermore cause rearrangement into	actomyosin fiber	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	cause rearrangement into	actomyosin fiber compose of coaligned f-actin	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	myosin assembly	furthermore cause rearrangement into	actomyosin fiber compose of coaligned f-actin	Furthermore , myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments .	79784	myosin	Gene	79784	myosin	Gene
1607384	severin-induced fragmentation	result in	immediate disassembly of myosin filament	Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .		severin	Chemical	79784	myosin	Gene
1607384	severin-induced fragmentation	result in	disassembly of myosin filament	Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .		severin	Chemical	79784	myosin	Gene
1607384	severin-induced fragmentation	be in	actomyosin fiber	Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .		severin	Chemical	79784	myosin	Gene
1607384	severin-induced fragmentation	result in	disassembly of myosin thick filament	Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .		severin	Chemical	79784	myosin	Gene
1607384	severin-induced fragmentation	result in	immediate disassembly of myosin thick filament	Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments , demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP .		severin	Chemical	79784	myosin	Gene
1607384	actomyosin fiber	also form after	addition of f-actin to 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	form after	addition of f-actin to 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	also form after	addition of f-actin to nonphosphorylated 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	also form after	addition to 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	also form after	addition to nonphosphorylated 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	form after	addition to nonphosphorylated 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	form after	addition of f-actin to nonphosphorylated 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	form after	addition to 10s myosin monomer	Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be spontaneously form by	f-actin-mediated assembly of muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be form by	assembly of muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be form by	f-actin-mediated assembly of muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be spontaneously form by	f-actin-mediated assembly of smooth muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be spontaneously form by	assembly of smooth muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be spontaneously form by	assembly of muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be form by	f-actin-mediated assembly of smooth muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
1607384	actomyosin fiber	be form by	assembly of smooth muscle myosin	The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin .	79784	myosin	Gene	79784	myosin	Gene
25495467	knowledge questionnaire	be valid across	multiple profession	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	multiple profession	involve in	pain management	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D010146	pain	Disease
25495467	knowledge questionnaire	be valid across	profession	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	knowledge questionnaire	be valid across	profession involve	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	profession	involve in	pain management	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D010146	pain	Disease
25495467	knowledge questionnaire	be valid across	multiple profession involve	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	knowledge questionnaire	be valid across	multiple profession involve in pain management	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D010146	pain	Disease
25495467	knowledge questionnaire	be valid across	profession involve in pain management	A modified evidence-based practice - knowledge , attitudes , behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management .	MESH:D009584	n	Chemical	MESH:D010146	pain	Disease
25495467	evidence-based practice	be in	medical trainee	Background A validated and reliable instrument was developed to knowledge , attitudes and behaviours with respect to evidence-based practice -LRB- EBB-KABQ -RRB- in medical trainees but requires further adaptation and validation to be applied across different health professionals .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	medical trainee	in practice be	ebb-kabq	Background A validated and reliable instrument was developed to knowledge , attitudes and behaviours with respect to evidence-based practice -LRB- EBB-KABQ -RRB- in medical trainees but requires further adaptation and validation to be applied across different health professionals .	MESH:D009584	n	Chemical		ebb-kabq	Chemical
25495467	perception	be in	clinician	Methods A modified 33-item evidence-based practice scale -LRB- EBP-KABQ -RRB- was developed to evaluate EBP perceptions and behaviors in clinicians .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	construct validity	be	examine	Scaling properties -LRB- internal consistency , floor/ceiling effects -RRB- and construct validity -LRB- association with EBP activities , comparator constructs -RRB- were examined .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	association	be with	ebp activity	Scaling properties -LRB- internal consistency , floor/ceiling effects -RRB- and construct validity -LRB- association with EBP activities , comparator constructs -RRB- were examined .	MESH:D009584	n	Chemical	10682	ebp	Gene
25495467	confirmatory factor analysis	assess	4-domain structure ebp knowledge	A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .	MESH:D009584	n	Chemical	10682	ebp	Gene
25495467	factor analysis	assess	4-domain structure ebp knowledge	A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .	MESH:D009584	n	Chemical	10682	ebp	Gene
25495467	factor analysis	assess	outcomes/decisions	A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	confirmatory factor analysis	assess	structure ebp knowledge	A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .	MESH:D009584	n	Chemical	10682	ebp	Gene
25495467	factor analysis	assess	structure ebp knowledge	A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .	MESH:D009584	n	Chemical	10682	ebp	Gene
25495467	confirmatory factor analysis	assess	outcomes/decisions	A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge , attitudes , behavior , outcomes/decisions -RRB- .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	support for	priori construct validation hypothesis	Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach 's alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	high internal consistency	support for	priori construct validation hypothesis	Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach 's alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	consistency	support for	priori construct validation hypothesis	Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach 's alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	high consistency	support for	priori construct validation hypothesis	Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach 's alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	internal consistency	support for	priori construct validation hypothesis	Results The EBP-KABQ scale demonstrated high internal consistency -LRB- Cronbach 's alpha = 0.85 -RRB- , no evident floor/ceiling effects , and support for a priori construct validation hypotheses .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	demonstrate	promising psychometric property in sample	Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	demonstrate	promising property	Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	demonstrate	promising property in sample	Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	demonstrate	psychometric property in sample	Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	demonstrate	promising psychometric property	Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	ebp-kabq scale	demonstrate	property in sample	Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample .	10682	ebp-kabq	Gene	MESH:D009584	n	Chemical
25495467	supplementary material	contain	supplementary material	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12909-014-0263-4 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	electronic supplementary material	contain	supplementary material	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12909-014-0263-4 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25495467	electronic material	contain	supplementary material	Electronic supplementary material The online version of this article -LRB- doi : 10.1186 / s12909-014-0263-4 -RRB- contains supplementary material , which is available to authorized users .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1607393	circumsporozoite protein	bind specifically to	sulfated glycoconjugate	Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .	MESH:C061194	sporozoite	Chemical	MESH:D013431	sulfate	Chemical
1607393	circumsporozoite protein	bind to	sulfated glycoconjugate	Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .	MESH:C061194	sporozoite	Chemical	MESH:D013431	sulfate	Chemical
1607393	malaria sporozoite	bind specifically to	sulfated glycoconjugate	Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .	MESH:C061194	sporozoite	Chemical	MESH:D013431	sulfate	Chemical
1607393	malaria sporozoite	bind to	sulfated glycoconjugate	Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates .	MESH:C061194	sporozoite	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	also bind	sulfated glycoconjugate	The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	sporozoite	also bind	sulfated glycoconjugate	The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .	MESH:C061194	sporozoite	Chemical	MESH:D013431	sulfate	Chemical
1607393	sporozoite	bind	sulfated glycoconjugate	The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .	MESH:C061194	sporozoite	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	bind	sulfated glycoconjugate	The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	recombinant P. yoelii cs protein	be examine	bind to sulfated glycoconjugate-sepharose	To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	P. yoelii cs protein	be examine	bind to sulfated glycoconjugate-sepharose	To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	P. yoelii cs protein	bind to	sulfated glycoconjugate-sepharose	To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	recombinant P. yoelii cs protein	bind to	sulfated glycoconjugate-sepharose	To test this hypothesis , recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	bind with	affinity to heparan sulfate mutant cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	also bind with	affinity to heparan sulfate biosynthesis-deficient cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	also bind with	affinity to heparan sulfate biosynthesis-deficient mutant cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	also bind with	lower affinity to heparan sulfate cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	also bind with	affinity to heparan sulfate cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	bind with	affinity to heparan sulfate biosynthesis-deficient mutant cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	also bind with	affinity to heparan sulfate mutant cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	bind with	affinity to heparan sulfate biosynthesis-deficient cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	bind with	affinity to heparan sulfate cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein	bind with	lower affinity to heparan sulfate cell line	CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild - type line , consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells .		cs	Chemical	MESH:D013431	sulfate	Chemical
1607393	cs protein binding	be inhibit by	fucoidan	This possibility is consistent with the observation that CS protein binding to hepatocytes , cells invaded by sporozoites during the primary stage of malaria infection , was inhibited by fucoidan , pentosan polysulfate , and heparin .		cs	Chemical	MESH:C007789	fucoidan	Chemical
1607393	P. berghei sporozoite	bind specifically to	sulfatide	P. berghei sporozoites bound specifically to sulfatide -LRB- galactosyl -LSB- 3-sulfate -RSB- beta 1-1ceramide -RRB- , but not to comparable levels of cholesterol-3-sulfate , or several examples of neutral glycosphingolipids , gangliosides , or phospholipids .	MESH:C061194	sporozoite	Chemical	MESH:D013433	sulfatide	Chemical
1607393	P. berghei sporozoite	bind to	sulfatide	P. berghei sporozoites bound specifically to sulfatide -LRB- galactosyl -LSB- 3-sulfate -RSB- beta 1-1ceramide -RRB- , but not to comparable levels of cholesterol-3-sulfate , or several examples of neutral glycosphingolipids , gangliosides , or phospholipids .	MESH:C061194	sporozoite	Chemical	MESH:D013433	sulfatide	Chemical
1607393	sporozoite invasion	parallel	observe binding of cs protein to sepharose derivative	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical		cs	Chemical
1607393	sporozoite invasion	be inhibit by	fucoidan	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical	MESH:C007789	fucoidan	Chemical
1607393	sporozoite invasion	parallel	binding of cs protein	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical		cs	Chemical
1607393	sporozoite invasion	parallel	observe binding of cs protein	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical		cs	Chemical
1607393	sporozoite invasion	parallel	observe binding of cs protein to corresponding sepharose derivative	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical		cs	Chemical
1607393	sporozoite invasion	parallel	binding of cs protein to corresponding sepharose derivative	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical		cs	Chemical
1607393	sporozoite invasion	parallel	binding of cs protein to sepharose derivative	Sporozoite invasion into hepatocytes was inhibited by fucoidan , heparin , and dextran sulfate , paralleling the observed binding of CS protein to the corresponding Sepharose derivatives .	MESH:C061194	sporozoite	Chemical		cs	Chemical
1607393	sporozoite infectivity	be significantly inhibit by	dextran sulfate 500,000	Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan .	MESH:D007239	sporozoite infectivity	Disease	MESH:D016264	dextran sulfate	Chemical
1607393	sporozoite infectivity	be inhibit by	dextran sulfate 500,000	Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan .	MESH:D007239	sporozoite infectivity	Disease	MESH:D016264	dextran sulfate	Chemical
25568636	parent-child-educator	postulate warrant child education of	child education	Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .	9606	child	Species	9606	child	Species
25568636	parent-child-educator	postulate warrant child education of	preschool child education	Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .	9606	child	Species	9606	child	Species
25568636	parent-child-educator	postulate	warrant child education	Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .	9606	child	Species	9606	child	Species
25568636	parent-child-educator	postulate	warrant successful preschool child education	Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .	9606	child	Species	9606	child	Species
25568636	parent-child-educator	postulate	warrant preschool child education	Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .	9606	child	Species	9606	child	Species
25568636	parent-child-educator	postulate	warrant successful child education	Only high-quality , synergistic relationship triad : parent-child-educator and the modern postulates of preschool child education , warrants successful preschool child education .	9606	child	Species	9606	child	Species
1607391	n2a cell adhesion	depend on	amount of NCAM apply to substratum	N2A cell adhesion depended on the amount of NCAM applied to the substratum , was cation independent , and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D .	CVCL:G626	n2a	CellLine	428253	ncam	Gene
1607391	n2a cell adhesion	depend on	amount of NCAM	N2A cell adhesion depended on the amount of NCAM applied to the substratum , was cation independent , and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D .	CVCL:G626	n2a	CellLine	428253	ncam	Gene
1607391	n2a cell adhesion	depend on	amount of NCAM apply	N2A cell adhesion depended on the amount of NCAM applied to the substratum , was cation independent , and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D .	CVCL:G626	n2a	CellLine	428253	ncam	Gene
1607382	insulin	stimulate	movement of two glucose transporter isoform	Insulin stimulates the movement of two glucose transporter isoforms -LRB- GLUT1 and GLUT4 -RRB- to the plasma membrane -LRB- PM -RRB- in adipocytes .	3630	insulin	Gene	MESH:D005947	glucose	Chemical
1607382	glut4 labeling	be increase after	insulin treatment	Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment , labeling of uncoated PM regions was markedly increased with insulin .	6517	glut4	Gene	3630	insulin	Gene
1607382	glut4 labeling	be only slightly increase after	insulin treatment	Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment , labeling of uncoated PM regions was markedly increased with insulin .	6517	glut4	Gene	3630	insulin	Gene
1607382	glut4 labeling	be slightly increase after	insulin treatment	Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment , labeling of uncoated PM regions was markedly increased with insulin .	6517	glut4	Gene	3630	insulin	Gene
1607382	glut4	recycle in	presence of insulin	These data suggest that GLUT4 recycles from the cell surface both in the presence and absence of insulin .	6517	glut4	Gene	3630	insulin	Gene
1607382	gtp gamma s	increase pm level	observe with insulin	In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .	MESH:D016244	gtp gamma s	Chemical	3630	insulin	Gene
1607382	gtp gamma s	increase pm level	observe with insulin in intact cell	In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .	MESH:D016244	gtp gamma s	Chemical	3630	insulin	Gene
1607382	gtp gamma s	increase	pm level of glut4	In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .	MESH:D016244	gtp gamma s	Chemical	6517	glut4	Gene
1607382	gtp gamma s	observe with	insulin	In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .	MESH:D016244	gtp gamma s	Chemical	3630	insulin	Gene
1607382	gtp gamma s	increase pm level	observe with insulin in cell	In streptolysin-O permeabilized adipocytes , insulin , and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells .	MESH:D016244	gtp gamma s	Chemical	3630	insulin	Gene
1607382	PM glut4 level	be	in presence of atp similar to level	When insulin and GTP gamma S were added together , in the presence of ATP , PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually .	6517	glut4	Gene	MESH:D000255	atp	Chemical
1607382	PM glut4 level	be	in presence of atp similar to level observe	When insulin and GTP gamma S were added together , in the presence of ATP , PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually .	6517	glut4	Gene	MESH:D000255	atp	Chemical
1607382	PM glut4 level	be similar in	presence of atp	When insulin and GTP gamma S were added together , in the presence of ATP , PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually .	6517	glut4	Gene	MESH:D000255	atp	Chemical
1607382	insulin-stimulated movement	require atp in	insulin signaling pathway	We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .	3630	insulin	Gene	3630	insulin	Gene
1607382	insulin-stimulated movement	require	atp	We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .	3630	insulin	Gene	MESH:D000255	atp	Chemical
1607382	atp	insulin-stimulated movement of	glut4	We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .	MESH:D000255	atp	Chemical	6517	glut4	Gene
1607382	atp	movement of	glut4	We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .	MESH:D000255	atp	Chemical	6517	glut4	Gene
1607382	insulin-stimulated movement	require atp in	early insulin signaling pathway	We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein -LRB- s -RRB- at a later step -LRB- s -RRB- .	3630	insulin	Gene	3630	insulin	Gene
25568628	greater unemployment	be in	area	Conclusion : According to the results , we can see that the socioeconomic status of patients had an effect on the occurrence of dental caries and oral hygiene in patients in relation to the rural and urban areas , because we can see that by the number of respondents , the greater unemployment of parents in both , rural and urban areas , caused a host of other factors , which were , either , directly or indirectly connected with the development of caries .	MESH:D012211	re	Chemical	MESH:D012211	re	Chemical
25497491	Parkinson	's disease be	pd	Parkinson 's disease -LRB- PD -RRB- is not only characterized by motor disturbances but also , by cognitive , sensory , psychiatric and autonomic dysfunction .	MESH:D009584	n	Chemical	MESH:D010300	pd	Disease
25497491	pathogenic formation	be	however poorly understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	formation	be	however understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	pathogenic formation	be	however understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	pathogenic formation	be	poorly understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	pathogenic formation	be	understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	formation	be	poorly understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	formation	be	understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	pathogenic formation	be in	different brain area of pd patient	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	formation	be	however poorly understand	However , the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	widespread formation	be in	different brain area	However , new models are required that reflect the widespread and progressive formation of alpha-syn aggregates in different brain areas .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	such alpha-syn aggregation	be	induce	Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	such aggregation	be	induce	Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	aggregation	be	induce	Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	alpha-syn aggregation	be	induce	Such alpha-syn aggregation is induced in only a few animal models , for example perikaryon inclusions are found in rats administered rotenone , aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn , and in Smad3 deficient mice , aggregates form extensively in the perikaryon and neurites of specific brain nuclei .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	alpha-syn aggregation	be in	human disorder	In this review we focus on alpha-syn aggregation in the human disorder , its genetics and the availability of experimental models .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	link between two pathological hallmark of pd	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	link between two hallmark	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	link	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	interesting link between two hallmark	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	interesting link	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	link between two pathological hallmark	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	interesting link between two pathological hallmark of pd	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	link between two hallmark of pd	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	interesting link between two pathological hallmark	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	suggest	interesting link between two hallmark of pd	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
25497491	dopamine metabolism	be relate to	alpha-syn	Indeed , evidences show that dopamine -LRB- DA -RRB- metabolism may be related to alpha-syn and its conformational plasticity , suggesting an interesting link between the two pathological hallmarks of PD : dopaminergic neurodegeneration and Lewy body -LRB- LB -RRB- formation .	MESH:D009584	n	Chemical	MESH:D009584	n	Chemical
1318884	cx40	be	mouse analogue	The highest overall homology detected , however , was to chick Cx42 -LRB- 67 % amino acid and 86 % nucleotide identity -RRB- , raising the possibility that Cx40 may be the mouse analogue .	14613	cx40	Gene	10090	mouse	Species
25568624	OverallSurvival	be in	Myelodysplastic Syndromes	Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes .	MESH:D000753	ra	Disease	MESH:D009190	myelodysplastic syndromes	Disease
25568624	peripheral blood cytopenia	can refine prediction in	mds	Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .	MESH:D000753	ra	Disease	MESH:D009190	mds	Disease
25568624	blood cytopenia	can refine prediction in	mds	Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .	MESH:D006402	cytopenia	Disease	MESH:D009190	mds	Disease
25568624	transfusion dependence	can refine prediction in	mds	Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .	MESH:D000753	ra	Disease	MESH:D009190	mds	Disease
25568624	performance status	can refine prediction in	mds	Age , gender , peripheral blood cytopenia , proportion of bone marrow -LRB- BM -RRB- blasts , performance status , comorbidities , transfusion dependence , specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS .	9606	man	Species	MESH:D009190	mds	Disease
25568583	sixty-one patient	be with	varicose vein	It was carried out at Clinic for vascular surgery in Sarajevo where fifty-eight -LRB- 58 -RRB- patients received surgical treatment for varicose veins and in Aesthetic Surgery Center `` Nasa mala klinika '' in Sarajevo were sixty-one -LRB- 61 -RRB- patients with varicose veins were treated by endovenous laser ablation .	9606	patient	Species	MESH:C077381	varicose	Chemical
25568583	pain	be	for seven day significantly higher in surgical group of patient	T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .	MESH:D010146	pain	Disease	9606	patient	Species
25568583	pain	be	for seven day significantly higher in group of patient	T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .	MESH:D010146	pain	Disease	9606	patient	Species
25568583	pain	be	for seven day higher in surgical group of patient	T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .	MESH:D010146	pain	Disease	9606	patient	Species
25568583	pain	compare to	evla group	T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .	MESH:D010146	pain	Disease		evla	Chemical
25568583	pain	be	for seven day higher in group of patient	T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups , for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group ; p < 0,05 .	MESH:D010146	pain	Disease	9606	patient	Species
25568583	evla	offer	better patient recovery	Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .		evla	Chemical	9606	patient	Species
25568583	evla	offer patient recovery in	term of significantly lower post treatment pain	Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .		evla	Chemical	MESH:D010146	pain	Disease
25568583	evla	offer	patient recovery	Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .		evla	Chemical	9606	patient	Species
25568583	evla	offer patient recovery in	term of lower post treatment pain	Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .		evla	Chemical	MESH:D010146	pain	Disease
25568583	evla	offer patient recovery in	term of post treatment pain	Conclusion : EVLA offers better patient recovery in terms of significantly lower post treatment pain , faster return to everyday activities and lower incidence of bruising -LRB- hematomas -RRB- .		evla	Chemical	MESH:D010146	pain	Disease